

07/18/00

Please type a plus sign (+) inside this box → +

07-19-00

PTO/SB/05 (2-98)  
Approved for use through 9/30/00 OMB 0651-0032  
Patent and Trademark Office U S DEPARTMENT OF COMMERCE


the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		<b>Attorney Docket No</b> 15060-00004  <b>First Named Inventor or Application Identifier</b> Richard W Gross  <b>Title</b> CALCIUM INDEPENDENT PHOSPHOLIPASE A <sub>2γ</sub> , POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS THEREFOR  <b>Express Mail Label No</b> EL319731036US
---	--	--

<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents.</small>		<b>ADDRESS TO</b> <b>Assistant Commissioner for Patents</b> <b>Box Patent Application</b> <b>Washington, DC 20231</b>
<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17)  <small>(Submit an original, and a duplicate for fee processing)</small></p> <p>2. <input checked="" type="checkbox"/> Specification  <small>(Preferred arrangement set forth below)</small> <ul style="list-style-type: none"> <li>- Descriptive title of the Invention</li> <li>- Cross References to Related Applications</li> <li>- Statement Regarding Fed sponsored R &amp; D</li> <li>- Reference to Microfiche Appendix</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings (<i>if filed</i>)</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul> </p> <p>3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113)      <b>[Total Sheets]</b> 32</p> <p>4. Oath or Declaration      <b>[Total Pages]</b> <input type="checkbox"/></p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d))  <small>(for continuation/divisional with Box 17 completed)</small>  <small>[Note Box 5 below]</small></p> <p>i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b>  <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</small></p> <p>5. <input type="checkbox"/> Incorporation by Reference (<i>useable if Box 4b is checked</i>)  <small>The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein</small></p>		
<p>6. <input type="checkbox"/> Microfiche Computer Program (<i>Appendix</i>)</p> <p>7. Nucleotide and/or Amino Acid Sequence Submission  <small>(If applicable, all necessary)</small> <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> Computer Readable Copy</li> <li>b. <input type="checkbox"/> Paper Copy (identical to computer copy)</li> <li>c. <input type="checkbox"/> Statement verifying identity of above copies</li> </ul> </p>		
<b>ACCOMPANYING APPLICATION PARTS</b>		
<p>8. <input type="checkbox"/> Assignment Papers (cover sheet &amp; document(s))</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement      <input type="checkbox"/> Power of Attorney  <small>(when there is an assignee)</small></p> <p>10. <input type="checkbox"/> English Translation Document (<i>if applicable</i>)</p> <p>11. <input type="checkbox"/> Information Disclosure      <input type="checkbox"/> Copies of IDS  <small>Statement (IDS)/PTO-1449</small>  <small>Citations</small></p> <p>12. <input type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503)  <small>(Should be specifically itemized)</small></p> <p>14. <input type="checkbox"/> Small Entity      <input type="checkbox"/> Statement filed in prior application,  <small>Statement(s)</small>      <small>Status still proper and desired</small>  <small>(PTO/SB/09-12)</small></p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s)  <small>(If foreign priority is claimed)</small></p> <p>16. <input checked="" type="checkbox"/> Other: Certificate of Express Mail, Declaration and Power of Attorney submitted for identification of inventor only.</p>		
<small>*NOTE FOR ITEMS 1 &amp; 14 IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 CFR §1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 CFR § 1.28)</small>		

<p>17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information</p> <p><input type="checkbox"/> Continuation      <input type="checkbox"/> Divisional      <input type="checkbox"/> Continuation-in-part (CIP)</p> <p>Prior application information      Examiner _____ Group/Art Unit _____ of prior application No _____</p>					
---	--	--	--	--	--

<b>18. CORRESPONDENCE ADDRESS</b>																													
<input type="checkbox"/> Customer Number or Bar Code Label <div style="border: 1px solid black; height: 20px; width: 200px; margin-top: 5px;"></div> <p style="text-align: center; font-size: small;">(Insert Customer No or Attach bar code label here)</p>			<input type="checkbox"/> or <input checked="" type="checkbox"/> Correspondence address below																										
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;">NAME</td> <td colspan="5">Donald R. Holland Armstrong Teasdale LLP</td> </tr> <tr> <td>ADDRESS</td> <td colspan="5">One Metropolitan Square Suite 2600</td> </tr> <tr> <td>CITY</td> <td>St Louis</td> <td>STATE</td> <td>MO</td> <td>ZIP CODE</td> <td>63102-2740</td> </tr> <tr> <td>COUNTRY</td> <td>U.S.A.</td> <td>TELEPHONE</td> <td colspan="2">(314) 621-5070</td> <td>FAX (314) 621-5065</td> </tr> </table>						NAME	Donald R. Holland Armstrong Teasdale LLP					ADDRESS	One Metropolitan Square Suite 2600					CITY	St Louis	STATE	MO	ZIP CODE	63102-2740	COUNTRY	U.S.A.	TELEPHONE	(314) 621-5070		FAX (314) 621-5065
NAME	Donald R. Holland Armstrong Teasdale LLP																												
ADDRESS	One Metropolitan Square Suite 2600																												
CITY	St Louis	STATE	MO	ZIP CODE	63102-2740																								
COUNTRY	U.S.A.	TELEPHONE	(314) 621-5070		FAX (314) 621-5065																								

Name (Print/type)	Donald R. Holland	Registration No. (Attorney/Agent)	35,197
Signature			Date July 18, 2000

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Office, Patent and trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT  
15060-00004

CERTIFICATE OF MAILING BY EXPRESS MAIL TO  
THE COMMISSIONER OF PATENTS AND TRADEMARKS


Express Mail mailing label number: EL319731036US

Date of Mailing: July 18, 2000

I certify that the attached utility patent application of **RICHARD W. GROSS and DAVID J. MANCUSO, for CALCIUM INDEPENDENT PHOSPHOLIPASE A<sub>2γ</sub> POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS THEREFOR** including:

- Fifty-one (51) pages of specification; Three (3) pages of claims; one (1) page of abstract
- Declaration and Power of Attorney, submitted for identification of inventors only (2 pgs)
- Thirty-two (32) sheets of drawings
- Patent Application Transmittal (1 page)
- Certificate of Mailing Via Express Mail (1 page)
- Return post card

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above in an envelope addressed to the Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231.

  
Donald R. Holland, Reg. No. 35,197  
Armstrong Teasdale LLP  
One Metropolitan Square, Suite 2600  
St. Louis, MO 63102  
314/621-5070

CALCIUM INDEPENDENT PHOSPHOLIPASE A<sub>2γ</sub>,  
POLYNUCLEOTIDES AND POLYPEPTIDES AND  
METHODS THEREFOR

REFERENCE TO GOVERNMENT GRANT

This invention was made with U.S. government support under National Institute of Health Grant Numbers 1 PO1 HL 57278-02, 2 RO2 HL 41250-08A1, and 5RO1 AA11094. The government has certain rights in this invention.

BACKGROUND OF THE INVENTION

(1) Field of the Invention

This invention relates to phospholipases and, more particularly, to novel calcium-independent phospholipase A<sub>2γ</sub> polypeptides and to nucleic acids encoding the polypeptides, as well as to methods of making and using the polypeptides and nucleic acids.

(2) Description of the Related Art

The function of complex biological organisms relies on the meticulous control of cellular activity, including the close regulation of cell growth, proliferation, and function. The family of enzymes known as the phospholipases A<sub>2</sub> has been implicated in the control of cellular activity by catalyzing the esterolytic cleavage of fatty acids from phospholipids, thereby regulating the release of lipid second messengers, cellular growth factors, and the properties of the cellular membrane. (Samuelsson et al., *Annu. Rev. Biochem.* 47:997-1029, 1978; Moolenaar, W.H., *Curr. Opin. Cell. Biol.* 7:203-10, 1995). In particular, by controlling the production of second messengers such as arachidonic acid and its biologically active eicosanoid metabolites, the phospholipases A<sub>2</sub> are involved in modulating such processes as cellular growth programs, inflammation, vascular tone and ion channel function. (Needleman et al., *Annu. Rev. Biochem.* 55:69-102, 1986).

However, the phospholipases A<sub>2</sub> are a broad family of enzymes with varying kinetic and physical properties, and distinct functions. Early research focused on distinguishing broad classes of the enzymes within the larger family. Several classes

were distinguished using *in vitro* activity assays, and are based on the dependence of enzyme activity on the presence calcium ion. (See e.g., Demel et al., *Biochim. Biophys. Acta* 406:97-107, 1975). Thus, one class, the secretory phospholipases A<sub>2</sub> are distinguished by an obligatory dependence on high (millimolar) concentrations of calcium ion, as well as low molecular weights (14-18 kDa) and relative heat stability.

5 (Demel et al., *supra*; Tischfield, J.A., *J. Biol. Chem.* 272:17247-50, 1997). The activity of a second class, the calcium-facilitated phospholipases A<sub>2</sub>, is facilitated by the presence of nanomolar concentrations of calcium ion, but the presence of the calcium ion is not obligatory. (Loeb et al., *J. Biol. Chem.* 261:10467-70, 1986; Kramer et al., 10 *Biochim. Biophys. Acta* 878:394-403; Glover et al., *J. Biol. Chem.* 270:15359-67, 1986). A third class of enzymes is entirely calcium-independent in *in vitro* studies, and is also distinguished by a finely tuned inhibition by (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one (BEL). (Wolf et al., *J. Biol. Chem.* 260:7295-303; Hirashima et al., *J. Neurochem.* 59:708-14; Lehman et al., *J. Biol. Chem.* 15 268:20713-16).

15 Application of molecular biological techniques has provided some insights into the structure and function of founding members in each class of phospholipases A<sub>2</sub>, and has provided a further basis for distinguishing among the classes. (See, e.g. Demel et al., *supra*; Evenberg et al., *J. Biol. Chem.* 252: 1189-96, 1977; Tischfeld, J.A., *J. Biol. Chem.* 272: 17247-50, 1997). For example, members of the secretory phospholipases A<sub>2</sub> use a calcium ion to polarize the *sn*-2-carbonyl for attack by a histidine-activated H<sub>2</sub>O molecule, while the intracellular phospholipases use a nucleophilic serine. The calcium-facilitated phospholipases A<sub>2</sub> have a GXSGS consensus lipase motif, in contrast to the iPLA<sub>2</sub> group which has a GXSTG consensus motif. The calcium-independent phospholipases A<sub>2</sub> are also distinguished by a consensus sequence for nucleotide binding. (Andrews et al., *Biochem. J.* 252:199-206, 1988; Tang et al., *J. Biol. Chem.* 272:8567-75, 1998). These findings have clearly boosted progress toward identifying the polypeptides responsible for catalyzing the synthesis of the eicosanoid metabolites and toward understanding the regulatory mechanisms of phospholipases A<sub>2</sub> that are involved in normal and disease states.

20 The more recent development of intense genome sequencing efforts have produced partial sequence data on the phospholipases, and related structural insights. For

example, two new calcium-facilitated phospholipases have recently been described based on data from protein and nucleotide data bases. (Underwood et al., *J Biol. Chem.* 273: 21926-32, 1998; Pickard et al., *J. Biol. Chem.* 274: 8823-31, 1999). Further, during sequencing of the long arm of chromosome 7 in the Human Genome Sequencing Project, a predicted protein product of 40kDa was identified. The polypeptide contained two ~10 amino acid segments homologous to the lipase and nucleotide-binding consensus sequences described for the founding members of the iPLA<sub>2</sub> family. (Tang et al., *supra*).

Some earlier work has suggested a connection between some types of phospholipases and certain disease conditions. For example, intensive study of reperfusion injury in myocardial tissue has led to the hypothesis that pathology is ultimately generated because of membrane phospholipid breakdown attributable to activation of myocardial phospholipase A<sub>2</sub> activity. (*See e.g.* Van der Vusse et al., *Hydrolysis of phospholipids and cellular integrity*, In: H.M. Piper (ed.) *Pathophysiology of Severe Ischemic Myocardial injury*, Kluwer Academic Publishers, Dordrecht, The Netherlands, 1990, 167-93). Furthermore, calcium-dependent and calcium-independent phospholipase A<sub>2</sub> activities have also been found to be present in human cerebral cortex. Some reports have suggested a possible link between the activity of phospholipases A<sub>2</sub>, both calcium-dependent calcium independent, and cortical degenerative diseases such as Alzheimer's disease. (For reviews, *see e.g.* Farooqui et al., *Neurochem. Int.* 30: 517-22, 1997; Farooqui et al., *Brain Res. Bull.* 49: 139-53, 1999).

Certain inhibitors of phospholipases A<sub>2</sub> have been identified as possible therapeutic candidates for treating PLA<sub>2</sub>-mediated diseases. For example, fatty acid trifluormethyl ketones, bromoenol lactone, methyl arachidonyl fluorophosphonate, bezenesulfonamides and other specific inhibitors of phospholipases A<sub>2</sub> have been shown to decrease PLA<sub>2</sub> activity and all have been considered for treating inflammatory diseases thought to be mediated by PLA<sub>2</sub>. (*See e.g.* Farooqui et al, 1999, *supra*). Nevertheless, as noted above, the phospholiapses A<sub>2</sub>, as well as the iPLA<sub>2</sub> subfamily itself, are a heterogeneous group of enzymes, with differing molecular weights, substrates, and responses to inhibitors. Because of this, the development of

agents for treating diseases mediated by these compounds is ideally based upon the structure and functional characteristics of the particular iPLA<sub>2</sub> involved in the disease process. Thus, it is crucial to identify and characterize the phospholipases A<sub>2</sub> in order to develop new drugs specific for those phospholipases A<sub>2</sub>.

5

## BRIEF SUMMARY OF THE INVENTION

Accordingly, the inventors herein have succeeded in discovering a novel phospholipase A<sub>2</sub>, referenced herein as calcium-independent phospholipase A<sub>2</sub>□ (iPLA<sub>2Y</sub>), and nucleic acids encoding iPLA<sub>2Y</sub>. The new calcium-independent phospholipase A<sub>2Y</sub> is involved with fatty acid β-oxidation in the peroxisomal compartment and is believed to be involved in certain disease processes. More specifically, the present invention is based on the collective work reported herein which identifies the complete genomic organization, nucleic acid sequence, and *sn*-2-lipase activity of a novel calcium-independent membrane-associated phospholipase A<sub>2</sub>.

Thus, in one embodiment, the invention is directed to an isolated nucleic acid molecule comprising a iPLA<sub>2Y</sub> polynucleotides. In one aspect of this embodiment, the iPLA<sub>2Y</sub> polynucleotides encode an iPLA<sub>2Y</sub> polypeptide. The iPLA<sub>2Y</sub> polypeptide catalyzes cleavage of fatty acids from the *sn*-2-position of phospholipids. Preferred sequences are as set forth in SEQ ID NO: 1 and SEQ ID NO: 2 which represent the amino acid sequences corresponding to alternative splice variants of iPLA<sub>2Y</sub>. Splice variants, identified herein as gamma 1 and gamma 2, involve splice sites 5' to the start codon so that both splice variants encode the same iPLA<sub>2Y</sub> polypeptide. Splice variant gamma 3, however, utilizes a start codon 5' to that of gamma 1 and gamma 2 to encode a longer polypeptide. SEQ ID NO:3 constitutes the cDNA of the coding region and SEQ ID NO:1 constitutes the encoded polypeptide of alternative splice variants gamma 1 and gamma 2. SEQ ID NO:4 constitutes the cDNA of the coding region of splice variant gamma 2 and SEQ ID NO:2 constitutes the encoded polypeptide.

The present invention is also directed to iPLA<sub>2Y</sub> polynucleotides and fragments thereof which specifically hybridize under stringent conditions to the complements of

the coding regions of iPLA<sub>2</sub>γ polynucleotides, the coding regions being set forth in SEQ ID NO:3 and SEQ ID NO:4 and the corresponding complements, SEQ ID NO:4 and SEQ ID NO:6, respectively. In another aspect of this embodiment, the present invention is directed to iPLA<sub>2</sub>γ polynucleotides comprising polynucleotides having at least about 90% identity with SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6 and, preferably, such polynucleotides comprise SEQ ID NO: 3, SEQ ID NO:4, SEQ ID NO: 5, or SEQ ID NO: 6.

In another aspect of this embodiment, the present invention is also directed to vectors and cells comprising an a polynucleotide encoding an iPLA<sub>2</sub>γ polynucleotide. In addition, the present invention encompasses antisense compounds which specifically hybridizes to SEQ ID NO: 3 or SEQ ID NO:4.

In one particular aspect of this embodiment, the present invention is directed to a fragment of an iPLA<sub>2</sub>γ polynucleotide comprising an iPLA<sub>2</sub>γ repressor binding site. Preferably, the polynucleotide comprises SEQ ID NO:7, 5'-  
15 TGATTCACGTTAGCTCAATT-3'.

In another embodiment, the present invention is directed to an isolated polypeptide comprising a phospholipase A2γ. The isolated polypeptide catalyzes cleavage of fatty acids from the *sn*-2-position of phospholipids. In one aspect of this embodiment, the polypeptide has at least about 90% identity with SEQ ID NO:1 or SEQ ID NO: 2 and, more preferably, the polypeptide comprises SEQ ID NO:1 or SEQ ID NO: 2. In another aspect of this embodiment, the present invention comprises a conservatively substituted variant of SEQ ID NO:1 or SEQ ID NO:2. The present invention also encompasses antibodies capable of binding to a phospholipase A2γ polypeptide.

Another embodiment of the present invention constitutes a method of treating inflammation in a patient. The method comprises treating the patient in to decrease calcium-independent phospholipase A<sub>2</sub>γ activity in the patient. It is contemplated that patients in need of such treatment include those patients suffering from Alzheimer's disease, myocardial ischemia, or myocardial infarction. Preferably, the method comprises administering to the patient a phospholipase A<sub>2</sub>γ translational repressor molecule. In another aspect of this invention, the method can also comprise

administering to the patient an antisense sequence which specifically hybridizes to SEQ ID NO: 3 or SEQ ID NO: 4.

In another embodiment, the present invention is directed to a method of increasing fatty acid utilization in a patient in need thereof. The method comprises 5 increasing iPLA<sub>2</sub>γ activity in the patient. Patients in need of such treatment include those patients suffering from diabetes as well as those patients suffering from obesity. Preferably, the method comprises administering to the patient a substance which blocks translational repression of iPLA<sub>2</sub>γ. In another aspect of this invention, the method can also comprise administering to the patient an iPLA<sub>2</sub>γ polypeptide or a 10 polynucleotide encoding said iPLA<sub>2</sub>γ polypeptide.

Another embodiment of the present invention is directed to a method for measuring activity of a phospholipase A<sub>2</sub>γ polypeptide of cells in a biological sample. The method comprises introducing into the sample a phospholipid substrate for cleavage of fatty acids by the phospholipase A<sub>2</sub>γ, wherein the phospholipase A<sub>2</sub>γ 15 cleaves fatty acid from the *sn*-2-position of the phospholipid substrate. The method further comprises measuring cleavage of the phospholipid substrate and/or quantifying the release of fatty acid from the substrate.

The present invention is also directed to an assay method for identifying substances which modulate iPLA<sub>2</sub>γ expression in a cell. The method comprises 20 contacting a candidate substance with cells comprising a promoter sequence operably linked to an iPLA<sub>2</sub>γ repressor binding site and a reporter gene and measuring expression of the reporter gene. By iPLA<sub>2</sub>γ repressor binding site it is meant that portion of nucleotide sequence of an iPLA<sub>2</sub>γ polynucleotide to which one or more endogenous substances within a cell bind to regulate translation of that iPLA<sub>2</sub>γ 25 polynucleotide. Preferably, the iPLA<sub>2</sub>γ repressor binding site comprises SEQ ID NO:7. The reporter gene, preferably, encodes an enzyme capable of being detected by a colorimetric, fluorimetric or luminometric assay such as, for example, a reporter sequence encoding a luciferase. In a particularly preferred embodiment, the promoter sequence is a baculovirus promoter sequence and the cells are Sf9 cells.

30 The present invention also encompasses genetically engineered cells capable of identifying substances which modulate iPLA<sub>2</sub>γ expression in a cell. The cells comprising a promoter operably linked to an iPLA<sub>2</sub>γ repressor binding site and a

reporter gene. Preferably, the iPLA<sub>2</sub>γ repressor binding site comprises SEQ ID NO:7. The reporter gene, preferably, encodes an enzyme capable of being detected by a colorimetric, fluorimetric or luminometric assay such as, for example, a reporter sequence encoding a luciferase. In a particularly preferred embodiment, the promoter sequence is a baculovirus promoter sequence and the cells are Sf9 cells.

5 The present invention also includes a method for identifying substances which modulate iPLA<sub>2</sub>γ expression. The method comprising contacting a candidate substance with cells capable of expressing iPLA<sub>2</sub>γ or a fragment thereof and measuring the expression of iPLA<sub>2</sub>γ or fragment thereof by the cells, wherein a level 10 of expression greater or less than that in absence of the substance indicates activity in modulating iPLA<sub>2</sub>γ expression.

15 Among the several advantages found to be achieved by the present invention, therefore, may be noted the provision of a novel phospholipase A<sub>2</sub>γ, iPLA<sub>2</sub>γ, which catalyzes the release of fatty acids from the *sn*-2-position of phospholipid substrate; the provision of methods for identifying a substance which represses and thus controls iPLA<sub>2</sub>γ expression in a sample; the provision of methods for treating diseases involving inflammatory processes, inflammation or fatty acid utilization; and the provision of methods for determining the presence and level of activity or expression of iPLA<sub>2</sub>γ in a sample.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20 Figure 1 shows the iPLA<sub>2</sub>γ cDNA sequence (SEQ ID NO:8) which contains the coding region for the 88kDa iPLA<sub>2</sub>γ polypeptide along with the corresponding amino acid sequence (SEQ ID NO:9).

Figure 2 illustrates three alternative splice variants of the iPLA<sub>2</sub>γ gene.

25 Figure 3 illustrates the 5' portion of three alternative splice variants, identified as 1 (SEQ ID NO:10), 2 (SEQ ID NO:11) and 3 (SEQ ID NO:12) along with amino terminal portion of the encoded polypeptides corresponding to splice variants 1 and 2 (SEQ ID NO:13) and splice variant 3 (SEQ ID NO:14).

Figure 4 illustrates the full-length 88kDa polypeptide (SEQ ID NO:1) and the cDNA encoding the polypeptide (SEQ ID NO:3) along with sense primer, M444 (SEQ ID NO:15) and reverse primer, M458 (SEQ ID NO:16) used in the PCR amplification of the 88kDa polypeptide.

5                  Figure 5 illustrates the 77kDa truncated polypeptide starting at amino acid 101 and nucleotide 301 (SEQ ID NO:17) and the cDNA encoding the polypeptide (SEQ ID NO:18) along with sense primer, m533 (SEQ ID NO:19) and reverse primer, M458 (SEQ ID NO:20) used in the PCR amplification of the 74kDa polypeptide.

10                Figure 6 illustrates the 74kDa truncated polypeptide starting at amino acid 122 and nucleotide 364 (SEQ ID NO:21) and the cDNA encoding the polypeptide (SEQ ID NO:22) along with sense primer, m534 (SEQ ID NO:23) and reverse primer, M458 (SEQ ID NO:24) used in the PCR amplification of the 74kDa polypeptide.

15                Figure 7 illustrates the 63kDa truncated polypeptide starting at amino acid 221 and nucleotide 661 (SEQ ID NO:25) and the cDNA encoding the polypeptide (SEQ ID NO:26) along with sense primer, m530 (SEQ ID NO:27) and reverse primer, M458 (SEQ ID NO:28) used in the PCR amplification of the 74kDa polypeptide.

20                Figure 8 is a schematic illustration mapping expressed sequence tags overlapping the full-length sequence of iPLA<sub>2</sub>γ.

Figure 9 illustrates the analysis of PCR amplified human iPLA<sub>2</sub>γ on agarose gel.

25                Figure 10 is a schematic representation of the strategy used for sequencing a PCR product encoding iPLA<sub>2</sub>γ.

Figure 11 is a hydropathy plot of the deduced amino acid sequence of human iPLA<sub>2</sub>γ.

Figure 12 is a Northern blot of human iPLA<sub>2</sub>γ mRNA obtained from multiple tissue samples.

Figure 13 is a schematic illustration of the genomic organization of the human iPLA<sub>2</sub>γ gene.

5           Figure 14 shows the results of gel electrophoresis and autoradiographic visualization of the *in vitro* translation products of iPLA<sub>2</sub>γ.

Figure 15 shows the results of Western analysis of iPLA<sub>2</sub>γ expression in Sf9 cells.

10          Figure 16 is a graph of an initial rate analysis of the iPLA<sub>2</sub> activity of iPLA<sub>2</sub>γ.

Figure 17 is a substrate selectivity profile of the iPLA<sub>2</sub> activity of iPLA<sub>2</sub>γ.

Figure 18 is a graph of inhibition of iPLA<sub>2</sub> activity of iPLA<sub>2</sub>γ by BEL.

15          Figure 19 shows the results of Western analysis of expression of truncated iPLA<sub>2</sub>γ constructs in Sf9 cells.

Figure 20 is a schematic representation of iPLA<sub>2</sub>γ translational repression constructs.

Figure 21 is a schematic representation of the pFASTBAC vector containing gamma 23mer sequences and luciferase coding sequence.

20          Figure 22 is a schematic representation of baculovirus promoter constructs containing gamma 23mer sequences and luciferase coding sequence.

Figure 23 shows phosphorylated oligo pairs for sequences between nucleotides 364 and 455 for use in translational repression of iPLA<sub>2</sub>γ in the luciferase expression system.

Figure 24 is a bar graph showing luciferase assay results showing the relative levels of expression of three different iPLA<sub>2</sub>γ constructs in Sf9 cells.

#### DETAILED DESCRIPTION OF THE INVENTION

Thus, the present invention is based upon the identification, isolation and sequencing of the novel calcium-independent phospholipase A<sub>2</sub>, iPLA<sub>2</sub>γ. The new iPLA<sub>2</sub>γ is both membrane-associated and highly sensitive to inhibition by (E)-6-  
5 (bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one (BEL), which distinguishes the new iPLA<sub>2</sub>γ from previously reported membrane-associated phospholipases A<sub>2</sub>. Prior to this invention, iPLA<sub>2</sub>γ was unknown and had not been distinguished as a biologically active substance discrete from known calcium-  
10 independent phospholipases A<sub>2</sub>, nor had it been isolated in pure form and its putative sequenced determined.

Reference to iPLA<sub>2</sub>γ or iPLA<sub>2</sub>γ polypeptides herein is intended to be construed to include the polypeptides corresponding to coding regions of three spliced variants identified herein. The amino acid sequences of the polypeptides are as set forth in SEQ ID NO:1 and SEQ ID NO:2. The coding portion of the cDNA of the splice variants are as set forth in SEQ ID NO:3 (splice variants gamma 1 and gamma 2) and SEQ ID NO:4 (splice variant gamma 3) (see Figures 2-4). The iPLA<sub>2</sub>γ polypeptides within the present invention are also intended to include iPLA<sub>2</sub>γ's of any origin which are substantially identical to and which are biologically equivalent to the iPLA<sub>2</sub>γ polypeptides characterized and described herein. Such substantially identical iPLA<sub>2</sub>γ's may be native to any tissue or species and, similarly, biological activity can be characterized in any of a number of biological assay systems. The term "biologically equivalent" is intended to mean that the compositions of the present invention are capable of demonstrating some or all of the same *sn*-2-lipase activity, membrane localization and sensitivity to BEL inhibition, not necessarily to the same degree as the iPLA<sub>2</sub>γ isolated herein as described in the examples below.  
15  
20  
25

By "substantially identical" it is meant that the degree of identity of human iPLA<sub>2</sub>γ to the iPLA<sub>2</sub>γ from any species is greater than that between the iPLA<sub>2</sub>γ and any previously reported member of the iPLA<sub>2</sub> family. Sequence identity or percent identity is intended to mean the percentage of same residues between two sequences when the two sequences are aligned by methods well known to those skilled in the art (for example, see Higgins et al, Cabios 8:189-191, 1992; Dayhoff et al., in ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, Dayhoff, Ed., NDRF, Washington, Vol. 5, suppl. 3, p. 345, 1978).

Polypeptides considered to be included within the term iPLA<sub>2</sub> polypeptides also includes conservatively substituted variants of SEQ ID NO:1 or SEQ ID NO:2. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups include: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine, glutamic acid-aspartic acid, leucine-methionine; glutamine-histidine.

The iPLA<sub>2</sub>γ polynucleotides of the present invention include those nucleic acid molecules, both DNA and RNA, which encode the iPLA<sub>2</sub>γ polypeptides. Such iPLA<sub>2</sub>γ polypeptides include, in particular, the coding regions of splice variants as set forth in SEQ ID NO:3 (splice variants gamma 1 and gamma 2) and SEQ ID NO:4 (splice variant gamma 3) (see Figures 2-4) as well as their complements, SEQ ID NO:4 and SEQ ID NO:6, respectively. Also included are cDNA sequences which show at least 20% identity with the cDNA sequences of SEQ ID NOS:3, 4, 5 or 6 as defined above and sequences which specifically hybridize to SEQ ID NOS:3, 4, 5 or

6. By specifically hybridizing to said sequences, it is meant that a given sequence hybridizes under high stringency conditions. The stringency of hybridization is determined by a number of factors during hybridization and during the washing procedure, including temperature; ionic strength, length of time and concentration of formamide. These factors are outlined in, for example, Sambrook et al. (Sambrook et al. Molecular Cloning: A Laboratory Manual, 2d ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). High stringency conditions serve to prevent false positives, that is the hybridization and apparent detection of iPLA<sub>2</sub>γ polynucleotide sequences when in fact an intact and functioning iPLA<sub>2</sub>γ polynucleotide is not present.

10 Probes and primers which are capable of hybridizing to an iPLA<sub>2</sub>γ sequence are also included within the present invention. Probes can be oligonucleotides of from about 25 to about 100 nucleotides in length which specifically hybridize to a target sequence. Primers within the scope of the present invention are typically short strands of DNA or RNA having a length of at least from about 6 to about 8 nucleotides, more preferably about 12 nucleotides, still more preferably about 15 nucleotides, and most preferably about 20 to about 30 nucleotides or greater in length. Such nucleic acid sequences hybridize to the target region. The primers herein are selected to be "substantially" complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand.

15 20 Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the strand to hybridize therewith and thereby form the template for the synthesis of the extension product.

25 30 The present invention also thus includes fragments and truncated polynucleotides which can be used in modulating the translational regulation of

iPLA<sub>2</sub>γ, and in the identification of naturally occurring repressor substances within the cell. Thus, by cloning of portions of the wild type iPLA<sub>2</sub>γ polynucleotide into a vector one can identify those portions of the sequence involved in translational regulation within the cell. These polynucleotide portions of the iPLA<sub>2</sub>γ sequence can bind to  
5 naturally occurring repressor substances in a cell and serve as binding ligands to the repressor substance. Such binding can block the decrease in iPLA<sub>2</sub>γ polynucleotide expression action that would otherwise occur if the repressor substance were free to bind to the iPLA<sub>2</sub>γ polynucleotide. In addition, the binding to a repessor substance by the polynucleotides can serve as a basis for identifying and isolating new compounds  
10 which prevent the binding of the repressor substance to iPLA<sub>2</sub>γ polynucleotides. Such binding to the repressor substance produces a de-repressor action to allow an increased expression of iPLA<sub>2</sub>γ polynucleotides.

The present invention also includes treatment of certain diseases using iPLA<sub>2</sub>γ, protein products thereof, or a translational repressor molecule thereof. Based on its genomic characterization and biological activity, iPLA<sub>2</sub>γ is a likely candidate for involvement in a number of disease processes. Without being bound to a particular theory, the inventors herein have discovered that iPLA<sub>2</sub>γ is a likely candidate for involvement in Alzheimer's disease because its *sn*-2-lipase activity regulates the release of lipid second messengers. Such second messengers include arachidonic acid and its eicosanoid metabolites which are prominent lipid second messengers for inflammatory processes. (See e.g. Needleman et al., *supra*). It has been previously established that the neural damage underlying Alzheimer's disease ultimately results from a final common pathway involving precipitation of amyloid protein in a plaque formation that initiates lipid inflammation and produces dystrophic changes in the affected neurons. The amyloid plaques of Alzheimer's disease are a nidus for localized inflammation, and the neural dystrophic process in Alzheimer's disease is characterized by the presence of several biochemical markers of inflammation, and inflammation may be the proximal cause of synaptic loss during neural dystrophy. (See e.g. Farooqui et al., *supra*). Thus, the inventors herein have, in  
20 identifying and characterizing iPLA<sub>2</sub>γ, also succeeded in identifying iPLA<sub>2</sub>γ as a new  
25  
30

candidate for mediating inflammatory processes involved in Alzheimer's disease. Treatment for Alzheimer's disease would thus involve any treatment that decreases the activity of iPLA<sub>2</sub>γ, especially in brain regions affected by Alzheimer's disease.

The iPLA<sub>2</sub>γ polypeptides of the present invention can also be used in the treatment of atherosclerotic heart disease, which represents a major cause of morbidity and mortality in the United States and other industrialized nations. In patients with myocardial infarction, the infarct size and type (i.e. transmural or subendocardial) profoundly affect realignment and remodeling of affected myocardial zones, and hence affect whether the infarct results in heart failure, or merely electrophysiologic dysfunction. Recent experimental results have shown that agents that enhance the efficiency of ATP production from the available O<sub>2</sub> supply have a salutary effect on the size and type of myocardial infarction. These findings implicate the phenomenon known as oxygen wasting, and pose as therapeutic candidates any agents that may have a beneficial effect on the efficiency of O<sub>2</sub> utilization by reducing oxygen wasting. In normal myocardium, most fatty acid oxidation occurs in the mitochondrial compartment, while a smaller but not insignificant portion of fatty acid oxidation, about 3-4%, occurs in peroxisomes. In the peroxisomal compartment, fatty acid oxidation occurs without generating reducing equivalents or ATP, thus producing no useful energy but only heat, resulting in oxygen wasting. During myocardial ischemia, mitochondrial oxidation of fatty acids is impaired to about 10% of normal levels. Thus, the oxygen wasted in the peroxisomal compartment gains greater significance because oxygen availability becomes rate-limiting. Therefore, reduction in oxygen wasting in the peroxisomal compartment during myocardial ischemia is likely to profoundly benefit myocyte preservation with attendant desirable effects on the clinical sequelae of ischemia or infarct. Thus, the inventors herein have, in identifying and characterizing iPLA<sub>2</sub>γ, have also succeeded in identifying iPLA<sub>2</sub>γ as a new candidate target for limiting oxygen wasting. Treatment for myocardial ischemia or myocardial infarction would thus also involve any treatment that decreases the activity of iPLA<sub>2</sub>γ, especially in ischemic heart tissue.

One approach for decreasing the activity of iPLA<sub>2</sub>γ is by the identification and administration to the cell, a translational repressor substance which decreases translation of iPLA<sub>2</sub>γ or administration of the nucleic acid encoding the translational repressor substance. Such repressor molecules can be identified by virtue of their binding to translational repressor binding sites identified herein.

Alternatively, iPLA<sub>2</sub>γ activity can be decreased by treatment with iPLA<sub>2</sub>γ antisense oligonucleotides. Such antisense oligonucleotides interact through base pairing with a specific complementary nucleic acid sequence involved in the expression of iPLA<sub>2</sub>γ such that the expression of iPLA2 is reduced. The iPLA<sub>2</sub>γ antisense oligonucleotides preferably comprise a sequence containing from about 8 to about 100 nucleotides and more preferably the iPLA<sub>2</sub>γ antisense oligonucleotides comprise from about 15 to about 30 nucleotides. The iPLA<sub>2</sub>γ antisense oligonucleotides can also contain a variety of modifications that confer resistance to nucleolytic degradation such as, for example, modified internucleoside linkages (Uhlmann and Peyman, *Chemical Reviews* 90:543-548 1990; Schneider and Banner, *Tetrahedron Lett.* 31:335, 1990), modified nucleic acid bases and/or sugars and the like.

Agents that regulate or control peroxisomal β-oxidation are also potentially useful in controlling the related diseases of obesity, hyperlipidemia and diabetes, which represent major health problems in the United States and other industrialized nations. Obesity and hyperlipidemia are primary features of Syndrome X, which identifies those at high risk for developing insulin-resistant (Type II) diabetes. Obesity and high serum lipid levels also predispose individuals to developing atherosclerosis and hypertension. Accordingly, agents that decrease body weight, serum lipid levels or the insulin-resistance characterizing Type II diabetes, are avidly sought. One type of such agents operates by increasing caloric expenditure or fatty acid β-oxidation, and significant reductions in body weight can be achieved with only small increases (about 2-3%) in caloric expenditure. Since fatty acid β-oxidation in peroxisomes wastes oxygen, producing only heat, and no energy in the form of NADH or ATP, an agent that thus increases caloric expenditure by increasing

peroxisomal fatty acid  $\beta$ -oxidation, directly or indirectly, has potentially major beneficial effects in the treatment of obesity, hyperlipidemia, diabetes, atherosclerosis and hypertension. Thus, the inventors herein have, in identifying and characterizing iPLA<sub>2</sub> $\gamma$ , also succeeded in identifying iPLA<sub>2</sub> $\gamma$  as a new candidate target for increasing 5 caloric expenditure by increasing peroxisomal fatty acid  $\beta$ -oxidation. Accordingly, treatment for the related diseases of diabetes, obesity, and hyperlipidemia would thus also involve any treatment that increases the activity of iPLA<sub>2</sub> $\gamma$ , especially in Type II diabetic or obese individuals.

The present invention, therefore, also includes therapeutic or pharmaceutical 10 compositions comprising iPLA<sub>2</sub> $\gamma$  polypeptides and polynucleotides as well as a blocker of iPLA<sub>2</sub> $\gamma$  translational repressor molecule, in an effective amount for treating patients with inappropriately low levels of iPLA<sub>2</sub> $\gamma$ . Such diseases include but are not limited to Type II diabetes, obesity and hyperlipidemia. The treatment can comprise 15 administering a therapeutically effective amount of iPLA<sub>2</sub> $\gamma$  polynucleotide or iPLA<sub>2</sub> $\gamma$  protein or a blocker of iPLA<sub>2</sub> $\gamma$  translational repression.

The therapeutic or pharmaceutical compositions of the present invention can be administered by any suitable route known in the art including for example intravenous, subcutaneous, intramuscular, transdermal, intrathecal or intracerebral. Administration can be either rapid as by injection or over a period of 20 time as by slow infusion or administration of slow release formulation.

iPLA<sub>2</sub> $\gamma$  can also be linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties. For example, iPLA<sub>2</sub> $\gamma$  can be coupled to any substance known in the art to promote penetration or transport across the blood-brain barrier such as an antibody to the transferrin receptor, and 25 administered by intravenous injection (See for example, Friden et al., *Science* 259:373-377, 1993). Furthermore, iPLA<sub>2</sub> $\gamma$  can be stably linked to a polymer such as polyethylene glycol to obtain desirable properties of solubility, stability, half-life and other pharmaceutically advantageous properties. (See for example Davis et al. *Enzyme Eng* 4:169-73, 1978; Burnham, *Am J Hosp Pharm* 51:210-218, 1994).

The compositions are usually employed in the form of pharmaceutical preparations. Such preparations are made in a manner well known in the pharmaceutical art. A preferred preparation utilizes a vehicle of physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers such as physiological concentrations of other non-toxic salts, five percent aqueous glucose solution, sterile water or the like may also be used. It may also be desirable that a suitable buffer be present in the composition. Such solutions can, if desired, be lyophilized and stored in a sterile ampoule ready for reconstitution by the addition of sterile water for ready injection. The primary solvent can be aqueous or alternatively non-aqueous. Calcium-independent phospholipase A<sub>2</sub>γ can also be incorporated into a solid or semi-solid biologically compatible matrix that can be implanted into tissues requiring treatment.

The carrier can also contain other pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the carrier may contain still other pharmaceutically acceptable excipients for modifying or maintaining release or absorption or penetration across the blood-brain barrier. Such excipients are those substances usually and customarily employed to formulate dosages for parenteral administration in either unit dosage or multi-dose form or for direct infusion into the cerebrospinal fluid by continuous or periodic infusion. Dose administration can be repeated depending upon the pharmacokinetic parameters of the dosage formulation and the route of administration used.

It is also contemplated that certain formulations containing iPLA<sub>2</sub>γ are to be administered orally. Such formulations are preferably encapsulated and formulated with suitable carriers in solid dosage forms. Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, gelatin, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium, stearate, water, mineral oil, and the like. The formulations can additionally include lubricating agents, wetting agents,

emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions may be formulated so as to provide rapid, sustained, or delayed release of the active ingredients after administration to the patient by employing procedures well known in the art. The formulations can also contain substances that diminish proteolytic degradation and promote absorption such as, for example, surface active agents.

The specific dose is calculated according to the approximate body weight or body surface area of the patient or the volume of body space to be occupied. The dose will also be calculated dependent upon the particular route of administration selected. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those of ordinary skill in the art. Such calculations can be made without undue experimentation by one skilled in the art in light of the activity disclosed herein in assay preparations of target cells. Exact dosages are determined in conjunction with standard dose-response studies. It will be understood that the amount of the composition actually administered will be determined by a practitioner, in the light of the relevant circumstances including the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration.

In a number of circumstances it would be desirable to determine the levels of containing iPLA<sub>2</sub>γ in a patient sample. The term "detection" as used herein in the context of detecting the presence of iPLA<sub>2</sub>γ in a patient is intended to include the determining of the amount of iPLA<sub>2</sub>γ or the ability to express an amount of iPLA<sub>2</sub>γ in a patient, the distinguishing of iPLA<sub>2</sub>γ from other phospholipases A<sub>2</sub>, the estimation of prognosis in terms of probable outcome of a degenerative disease and prospect for recovery, the monitoring of iPLA<sub>2</sub>γ levels over a period of time as a measure of status of the condition, and the monitoring of iPLA<sub>2</sub>γ levels for determining a preferred therapeutic regimen for the patient.

To detect the presence of iPLA<sub>2</sub>γ in a patient, a sample is obtained from the patient. The sample can be a tissue biopsy sample or a sample of blood, plasma, serum, CSF or the like. Samples for detecting iPLA<sub>2</sub>γ can be taken from any of these tissues. To detect the presence of iPLA<sub>2</sub>γ, an enzymatic analysis or Western blot analysis can be performed.

The term "probe" as used herein refers to a structure comprised of a polynucleotide which forms a hybrid structure with a target sequence, due to complementarity of probe sequence with a sequence in the target region. Oligomers suitable for use as probes may contain a minimum of about 8-12 contiguous nucleotides which are complementary to the targeted sequence and preferably a minimum of about 20, more preferably a minimum of about 25, still more preferably a minimum of about 30, yet still more preferably a minimum of about 40, and most preferably a minimum of about 50. Calcium-independent A<sub>2</sub>γ gene probes of the present invention can be DNA or RNA oligonucleotides and can be made by any method known in the art such as, for example, excision, transcription or chemical synthesis. Probes may be labeled with any detectable label known in the art such as, for example, radioactive or fluorescent labels or enzymatic marker. Labeling of the probe can be accomplished by any method known in the art such as by PCR, random priming, end labeling, nick translation or the like. One skilled in the art will also recognize that other methods not employing a labeled probe can be used to determine the hybridization. Examples of methods that can be used for detecting hybridization include Southern blotting, fluorescence in situ hybridization, and single-strand conformation polymorphism with PCR amplification.

Hybridization is typically carried out at 25.- 45. °C., more preferably at 32.degree.-40.degree. C. and more preferably at 37.degree.-38.degree. C. The time required for hybridization is from about 0.25 to about 96 hours, more preferably from about one (1) to about 72 hours, and most preferably from about 4 to about 24 hours.

The PCR method for labeling probes or amplifying target sequences uses primers that flank or lie within the target, here iPLA<sub>2</sub>γ, gene. The PCR method is

well known in the art. Briefly, this method is performed using two oligonucleotide primers which are capable of hybridizing to the nucleic acid sequences flanking a target sequence that lies within a iPLA<sub>2</sub>γ gene and amplifying the target sequence. The terms "oligonucleotide primer" as used herein refers to a short strand of DNA or RNA ranging in length from about 8 to about 50 bases. The upstream and downstream primers are typically from about 20 to about 30 base pairs in length and hybridize to the flanking regions for replication of the nucleotide sequence. The polymerization is catalyzed by a DNA-polymerase in the presence of deoxynucleotide triphosphates or nucleotide analogs to produce double-stranded DNA molecules. The double strands are then separated by any denaturing method including physical, chemical or enzymatic. Commonly, the method of physical denaturation is used involving heating the nucleic acid, typically to temperatures from about 80.degree. C. to 105.degree. C. for times ranging from about 1 to about 10 minutes. The process is repeated for the desired number of cycles.

The primers are selected to be substantially complementary to the strand of DNA being amplified. Therefore, the primers need not reflect the exact sequence of the template, but must be sufficiently complementary to selectively hybridize with the strand being amplified. Preferably, primers are at least 10 nucleotides long, more preferably at least 15 nucleotides long, still more preferably at least 20 nucleotides long, still more preferably at least 25 nucleotides long, still more preferably at least 30 nucleotides long, still more preferably at least 40 nucleotides long, and most preferably at least 50 nucleotides long. After PCR amplification, the DNA sequence comprising iPLA<sub>2</sub> or a fragment thereof is then directly sequenced and analyzed.

Exemplary embodiments of the invention are described in the following examples. Other alternative embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples.

The following methods were used in the examples below. Specific materials used in the work reported herein were as described herein, but those skilled in the art will recognize that many suitable alternative materials are readily available from commercial suppliers. [ $\alpha$ -<sup>32</sup>P]dCTP (6000Ci/mmol) and ECL detection reagents were purchased from Amersham Pharmacia Biotech. A human heart cDNA library was purchased from Stratagene, Inc. Human heart Marathon cDNA, QuickClone human skeletal cDNA, and human MTN multiple tissue Northern blots were purchased from CLONTECH. For PCR, a Perkin-Elmer Thermocycler was used, and all PCR reagents were purchased from PE Biosystems. The pGEM-T vector and TnT Quick Coupled Transcription/Translation System were purchased from Promega. Vector pcDNA1.1 was purchased from Invitrogen. Culture media, Cellfectin and LipofectAMINE reagents for transfection of baculovirus vectors, and competent DH110Bac *Escherichia coli* cells were purchased from Life Technologies, Inc., and used according to the manufacturer's protocol. QIAfilter plasmid kits and QIAquick gel extraction kits were obtained from Qiagen, Inc. Keyhole limpet hemocyanin was obtained from Pierce. L- $\alpha$ -1-dipalmitoyl-2-[1-<sup>14</sup>C]phosphatidylcholine, L- $\alpha$ -1-palmitoyl-2-[1-<sup>14</sup>C]oleoyl phosphatidylcholine, L- $\alpha$ -1-palmitoyl-2-[1-<sup>14</sup>C]linoleoyl phosphatidylcholine, and L- $\alpha$ -1-palmitoyl-2-[1-<sup>14</sup>C]arachidonoyl phosphatidylcholine were purchased from NEN Life Science Products. 1-*O*-(Z)-hexadec-1'-enyl-2-[9,10-<sup>3</sup>H]octadec-9'-enyl-*sn*-glycero-3-phosphocholine was synthesized and purified as described in Han et al., *Anal. Biochem.* 200:119-24, 1992, which is herein incorporated by reference. The luciferase assay kit used was that of Promega. BEL was obtained from Sigma. Any other reagents were also obtained primarily from Sigma. Searches of EMBL and NCBI data bases were performed using the Basic Local Alignment Search Tool (BLAST) (NCBI). Alignments of all sequences were performed using the MultiAlign computer program, as described in Corpet, F., *Nucleic Acids Res.* 16:10881-90, 1988, which is herein incorporated by reference.

Expression of iPLA<sub>2</sub> $\gamma$  in an intact eukaryotic system was evaluated using cultured *Spodoptera frugiperda* (Sf9) cells. Sf9 cells have been widely used to express recombinant proteins as a host cell in the baculovirus expression system. (See

e.g. Liu et al., *J. Immunol.* 156:3292-300, 1996). It is believed that the translational elements of Sf9 cells exhibit a high degree of homology with mammalian translational elements. (See e.g. Sakahira et al., *J. Biol. Chem.* 274:15740-4, 1999; Kimball et al., *J Biol. Chem.* 273:12841-5, 1998; Gu et al., *Biochim. Biophys. Acta* 1399:1-9, 1998).

5 Sf9 cells were grown and infected with wild-type or recombinant baculovirus containing human phospholipase A<sub>2</sub>γ cDNA as described in detail in Wolf, M.J. and Gross, R.W., *J. Biol. Chem.* 271:30879-85, 1996, which is herein incorporated by reference. Culture of Sf9 cells involved, in brief, placing Sf9 cells in growth medium in 100-ml spinner flasks equipped with a magnetic spinner. The rotation speed of the  
10 magnetic spinner was set at about 80 rpm, which is believed to be especially suitable for optimizing growth of Sf9 cells. The growth medium included Grace's medium supplemented with Yeastolate, Lactalbumin, 1% Antimycotic (all from Sigma), 10% fetal bovine serum and 1% Plutonic F-68 surfactant. Sf9 cells at a concentration of 1x10<sup>6</sup> cells/ml were prepared in 50 ml of the growth medium and incubated at 27°C  
15 for one (1) hour prior to infection with either wild-type baculovirus or recombinant baculovirus containing human phospholipase A<sub>2</sub>γ cDNA. After 48 hours, cells were repelleted by centrifugation, resuspended in ice-cold phosphate-buffered saline, and repelleted. All subsequent operation were performed at 4°C. The supernatant was decanted, and the cell pellet was resuspended in 5 ml homogenization buffer (25 mM imiazole, pH 8.0, 1 mM EGTA, 1mM dithiothreitol, 0.34 M sucrose, 20 MM  
20 transepoxysuccinyl-L-leucylamido-(4-guanidino) butane, and 2μg/ml leupeptin. Cells were lysed at 0°C by sonication (twenty (20) one-second bursts utilizing a Vibra-cell sonicator at a 30% output) and centrifuged at 100,000 x g for one (1) hour. The supernatant containing predominantly cytosol was saved, and the membrane pellet  
25 was washed with homogenization buffer and resuspended using a Teflon homogenizer in 6 ml of homogenization buffer. After a brief sonication (ten (10) one-second bursts), the mixture was subjected to recentrifugation at 100,000 x g for one (1) hour. After removal of the supernatant, the membrane pellet was resuspended in 1 ml homogenization buffer using a Teflon homogenizer and subsequently sonicated at 0°C  
30 for five (5) one-second bursts.

For PCR, primer design and selection of appropriate restriction sites for constructing vectors proceeded according to the following. The free software program Amplify 1.2 was used to design nucleotides containing appropriate terminal restriction sites. In general, oligonucleotides are at least 20 nucleotides long, with approximately 50% GC/AT ratio, and do not have a T at the 3' end. The Amplify program predicts the efficiency of nucleotide priming, the presence of primer dimer pairing, if any, and the predicted sizes and approximate amounts of products obtained. The iPLA<sub>2</sub> used for designing primers has been deposited in the GenBank™ database (accession number AF263613).

For PCR amplification of iPLA<sub>2</sub>γ, the reagents (10x PCR buffer, Mg buffer, dNTPs, and AmpliTaq) were obtained from PE Biosystems. Plugged pipet tips were used in all PCR procedures to minimize cross-contamination. PCR amplification occurred in the Perkin Elmer model 460 thermocycler. PCR reactions (50 µl) were set up as follows:

15	10x PCR buffer	50 µl
	Mg	3 µl
	10 mM dNTP mix	1 µl each
	sense primer	0.5 µl of 0.08 µM stock
	antisense primer	0.5 µl of 0.08 µM stock
20	DNA template	1 µl of miniprep (from a 50 µl miniprep stock)
	Sterile millipore water	35.75 µl

The thermocycler was programmed to heat the above reaction mixture for five minutes at 94 °C followed by two minutes at 80 °C during which 0.25 µl AmpliTaq and one drop of oil were added prior to initiation of the cycling program.

For typical PCR analysis, a 30-cycle program was employed, with steps at 53 °C for 30 seconds, 72 °C for two minutes, and 94 °C for 30 seconds per cycle. iPLA<sub>2</sub>γ was amplified utilizing oligonucleotides that flanked the predicted 5'- and 3'-coding region, M444 (5'-TTTGTCGACATGTCTATTAATCTGACTGTAGATA-3') (SEQ ID NO:29) and M449 (5'-

GCATACTCGAGTCACAATTGAAAAGAACATGGAAAGTCC-3')(SEQ ID NO:30), respectively to engineer appropriate restriction sites onto iPLA<sub>2</sub>γ for subsequent cloning into SalI/SphI restriction sites of a pFASTBAC vector (Life Technologies, Inc.). PCR screening was performed using human skeletal muscle cDNA (0.5 ng), human heart Marathon cDNA (0.5 ng) and a human heart cDNA library (approximately 1x10<sup>9</sup> plaque-forming units) as templates. To directly compare differences between the sequences reported herein and previously reported sequences, PCR amplification of sequence previously reported in a BAC genomic clone (Research Genetics) was used as a template, and PCR was performed with primers M452 (5'-GTACATACGGTGGACAAGCCTA-3')(SEQ ID NO:31) and M446 (5'-CATTCCTCTCCCTTCACTGGATCCACATAGCC-3')(SEQ ID NO:32).

All PCR products were resolved by 1% agarose gel electrophoresis. Candidate bands visualized with ethidium bromide staining were extracted from the agarose gel using the QIAquick Gel extraction kit from Qiagen. The extracted DNA and cloning vector (pFASTBAC) were restriction digested with appropriate restriction enzymes (SalI/SphI for the above primers), resolved on a 1% agarose gel, extracted with the QIAquick Gel extraction kit, and then ligated. In a typical ligation 2 to 10 molar excess restriction digested PCR product was ligated overnight at 16 °C to restriction digested vector in a 20 µl reaction using T4 DNA ligase (Promega). For transformation, Stratagene XL2-Blue MRF ultracompetent cells (#200151) were used according to the manufacturer's protocol. Following bacterial transformation and growth of transformants, plasmids were purified using a QIAfilter plasmid kit from QIAGEN, and subjected to automated sequence analysis using either an ABI 373S or 377XL automated DNA sequencer (PE Biosystems).

Bacmids were prepared from the pFASTBAC plasmid constructs using the bac-to-Bac Baculovirus Expression System protocol from Life technologies, Inc. In brief, pFASTBAC plasmid constructs were used to transform DH10Bac competent cells resulting in a Tn7 site-specific transposition to produce a composite bacmid containing the cloned sequence of interest. This bacmid was used in Cellfectin-mediated transfection of Sf9 cells in a 35 mm plates for 72 hours resulting in production of infectious recombinant baculovirus in the Sf9 cells. Recombinant baculovirus (1 ml) obtained was used to infect 50 ml of Sf9 cells in a 100 ml spinner for an additional 72 hours to provide a stock of amplified virus.

To prepare truncated iPLA<sub>2</sub>γ constructs in pFASTBAC, PCR primers containing appropriate restriction sites for cloning were used. For example, the original full-length construct was used as a template in PCR with a sense primer annealing at nt 650-676 paired with reverse primer M458 to create a truncated iPLA<sub>2</sub>γ (63kDapF) with a methionine start site corresponding to amino acid 221 in the full-length protein. expression of this construct in the baculovirus system resulted in a 63 kDa recombinant protein. A second construct was created with a start site corresponding to methionine 122 to produce a 74kDa recombinant protein. Additional constructs were prepared to produce Nterminal truncated recombinant proteins of approximately 77, 70 and 66kDa. Segments of iPLA<sub>2</sub>γ 5' sequence ranging between 15-663 nt were inserted 5' of the insert sequence in 63kDapF to identify potential sequences involved in translational regulation. These sequences were ligated as inframe 5' coding sequence or as 5' noncoding sequence to the 63kDapF construct. For recombinant protein produced in the Sf9 system as described herein, enzymatic activity was determined using the enzyme assay as described below in Example 6, and mass of each of these constructs was determined using Western analysis as described herein. Additionally, full-length truncated iPLA<sub>2</sub>γ and truncated iPLA<sub>2</sub>γ constructs were inserted 5' of full-length luciferase coding sequence which was cloned into pFASTBAC via NotI/XbaI restriction sites. Luciferase activity of recombinant protein produced in the Sf9 system was then measured using the Luciferase Assay System of Promega, as described in detail in Example 8 below. (Wood, K.V., (1991)

In: *Bioluminescence and Chemiluminescence: Current Status*, Stanley, P. and Kricka, L. eds., John Wiley and Sons, Chichester, NY, 543; and *Luciferase Assay System Technical Bulletin*, #TB101, Promega Corporation, 1996, which are herein incorporated by reference).

5           The unique ability of antibodies to recognize and specifically bind to target proteins provides an approach for treating an over expression of the protein. Thus, another aspect of the present invention provides for a method for preventing or treating diseases involving over expression of the iPLA<sub>2</sub>γ protein by treatment of a patient with specific antibodies to the iPLA<sub>2</sub>γ protein. Specific antibodies, either 10 polyclonal or monoclonal, to iPLA<sub>2</sub>γ protein can be produced by any suitable method known in the art. For example, the iPLA<sub>2</sub>γ protein, or an immunologically active fragment thereof, or an anti-idiotypic antibody, or fragment thereof can be administered to an animal to elicit the production of antibodies capable of recognizing and binding to the iPLA<sub>2</sub>γ protein. Such antibodies can be from any class of 15 antibodies including, but not limited to IgG, IgA, IgM, IgD, and IgE or in the case of avian species, IgY and from any subclass of antibodies. Polyclonal antibodies can be prepared by immunizing rabbits or other animals by injecting antigen followed by subsequent boosts at appropriate intervals. The animals are bled and sera assayed against purified iPLA<sub>2</sub>γ protein usually by ELISA or by bioassay based upon the 20 ability to block the activity of iPLA<sub>2</sub>γ protein in cells. When using avian species, e.g. chicken, turkey and the like, the antibody can be isolated from the yolk of the egg. Monoclonal antibodies can be prepared after the method of Milstein and Kohler by fusing splenocytes from immunized mice with continuously replicating tumor cells 25 such as myeloma or lymphoma cells. (Milstein and Kohler, *Nature* 256:495-497, 1975; Galfre and Milstein, METHODS IN ENZYMOLOGY: IMMUNOCHEMICAL TECHNIQUES 73:1-46, Langone and Banatis eds., Academic Press, 1981 which are incorporated by reference). The hybridoma cells so formed are then cloned by limiting dilution methods and supernates assayed for antibody production by ELISA, RIA or bioassay.

More specifically, to generate and purify the anti-iPLA<sub>2</sub>γ peptide polyclonal antibodies used in the work described herein, New Zealand white rabbits were immunized with the iPLA<sub>2</sub>γ synthetic peptide CENIPLDESRNEKLDQ (SEQ ID NO:33). This peptide (G3, 4 mg), dissolved in minimal volume of dimethylsulfoxide, 5 was conjugated to maleimide-activated keyhole limpet hemocyanin (KLH, 2 mg) in 200 μl of 83 mM sodium phosphate, 0.9 M NaCl , and 0.1 mM EDTA at 22 °C for two hours. After extensive dialysis against 83 mM sodium phosphate conatining 0.9 mM NaCl, a 1:1 emulsion was made with the peptide-KLH conjugate and Freund's complete adjuvant. This emulsion was then injected subcutaneously into two 10 anaesthetized New Zealand white rabbits. Two booster injections of a 1:1 emulsion of the peptide-KLH aonjugate and Freund's incomplete adjuvant were given two and four weeks after the initial immunization. Serum was then collected for purification of the anti iPLA<sub>2</sub>γ antibodies.

A peptide affinity column was generated by coupling the iPLA<sub>2</sub>γ synthetic peptide to a 15 thiopropyl-Sepharose (Amersham-Pharmacia) resin in the presence of 100 mM sodium citrate, pH 4.5. The resin-peptide suspension was mixed by inversion overnight at 22 °C. Coupling efficiency was monitored by the displacement of the 2-pyridyl sulfide groups as 2-thiypyridone through spectrophotometric monitoring at 343 nm. Before chromatography, the resin-peptide suspension was equilibrated with 20 10 mMTris-HCl, pH 7.5 in an Econo-pac column (BioRad) by gravity flow. Serum containing the anti the iPLA<sub>2</sub>γ antibodies was diluted 1:10 (v/v) with 10 mM tris-HCl, pH 7.5 and then applied to the peptide affinity column by gravity flow. The diluted serum was then re-applied twice to the column to assure binding of the antibody to the column. After washing the column extensively with 10 mM tris-Hcl, pH 7.5 25 containing 500 mM NaCl, bound anti-iPLA<sub>2</sub>γ antibody was eluted from the column with 100 mM glycine, pH 2.5 and the immediately neutralized with 100 mM Tris-hcl, pH 9.0. The antibody was then concentrated using Centricon-10 (Americon) centrifugal filter devices and stored at 40 °C until use.

This example illustrates the approach used in identifying the full-length cDNA encoding phospholipase A<sub>2</sub>γ.

Inspection of a sequence encoding a putative 40kDa phospholipase reported by the Human Genome Sequencing Project (BAC clone RG054D04; GenBank™ accession no. AC005058) demonstrated that the sequence did not begin with an initiator methionine codon. Thus, a TBLASTN data base search was undertaken to find expressed sequence tags (EST's) that might align with the 5'-end of the putative phospholipase sequence.

Six expressed sequence tags (EST's) identified in the TBLASTN search were mapped on the basis of their overlapping the 40kDa cDNA sequence or on the basis of their binding in close spatial proximity to the putative phospholipase sequence. Figure 8 is a schematic illustration showing this mapping. Amino acid numbering starting from the most 5' potential translation site is indicated by the scale at top, with a schematic representation of the previously identified putative 40-kDa phospholipase shown shaded below. The EST sequences that were used to identify a potential N-terminal initiator methionine and to map the full-length sequence of a novel phospholipase, calcium-independent phospholipase A<sub>2</sub>γ (iPLA<sub>2</sub>γ), are indicated by solid bars,. The accession number for each EST sequence is indicated above each solid bar. The arrows at bottom indicate the position and orientation of PCR primers M444 (5'-end) and M449 (3'-end) used to amplify a full-length 2.4-kb coding sequence for iPLA<sub>2</sub>γ from human heart cDNA.

Specifically, EST clones vz36b01.ri Soares 2NbMT *Mus musculus* cDNA IMAGE:1328521 (accession no. AA915661) and *Rattus norvegicus* cDNA UI-R-C0-hp-c-06-0-UI (accession no. AA998901) were found to overlap with the BAC clone sequence, thereby adding an additional 360 nt sequence to the previously known 5' end of the putative phospholipase sequence. Four other EST clones found in the GenBank™ database (Stratagene *Homo sapiens* colon cDNA clone IMAGE:588479, accession no. AA143503; Stratagene *H. sapiens* cDNA clone IMAGE:647744, accession no. AA205528; normalized rat ovary, Bento soares *Rattus* sp. CDNA clone

ROVAA46, accession no. AA801084; and NCI\_CGAP\_GCB1 *H. sapiens* cDNA clone IMAGE:825005, accession no. AA504219) were found to be in close spatial proximity to the putative phospholipase sequence from the BAC clone. However, when aligned with the BAC clone sequence, the 3'-end of the EST AA504219  
5 sequence and the 5'-end of EST AA998901 are separated by a 150-nt gap, as shown in Figure 8. Moreover, when the EST AA998901 sequence was back-translated through the gap and into EST AA504219, a continuous reading frame resulted. Thus, by overlapping known EST sequences and back-translating through the 150-nt gap, the inventors have succeeded in extending the putative phospholipase sequence  
10 approximately 1.2 kb upstream from the predicted GenBank™ protein product.

The furthest upstream ATG codon that remained in frame with the newly identified full-length coding sequence was located 1210 nt upstream from the previously reported BAC clone sequence. Translation of the reported gene sequence further 5' from nt 122761 in BAC clone RG054D04 results in stop codons in all three  
15 reading frames.

Based upon the predicted sequence obtained from this assembly of sequences in the database, primers were constructed to obtain and sequence the putative full-length phospholipase. For PCR, primer design and selection of appropriate restriction sites for constructing vectors proceeded according to the  
20 following. The free software program Amplify 1.2 was used to design nucleotides containing appropriate terminal restriction sites. In general, oligonucleotides are at least 20 nucleotides long, with approximately 50% GC/AT ratio, and do not have a T at the 3' end. The Amplify program predicts the efficiency of nucleotide priming, the presence of primer dimer pairing, if any, and the predicted sizes and approximate  
25 amounts of products obtained. The iPLA<sub>2</sub> used for designing primers has been deposited in the GenBank™ database (accession number AF263613).

PCR analysis used primers corresponding to the most 5' candidate initiator methionine and the known 3' stop codon (nt 79,673) in the gene sequence.

For typical PCR analysis, a 30-cycle program was employed with steps at 53 °C for 30 seconds, 72 °C for two minutes, and 94 °C for 30 seconds per cycle. iPLA<sub>2</sub>γ was amplified utilizing oligonucleotides that flanked the predicted 5'- and 3'-coding region, M444 (5'-TTTGTGACATGTCTATTAATCTGACTGTAGATA-3') and 5 M449 (5'-GCATACTCGAGTCACAATTGAAAAGAACATGGAAAGTCC-3'), respectively. PCR screening was performed using human skeletal muscle cDNA (0.5 ng), human heart Marathon cDNA (0.5 ng) and a human heart cDNA library (approximately 1x10<sup>9</sup> plaque-forming units) as templates. To directly compare differences between the sequences reported herein and previously reported sequences, 10 PCR amplification of sequence previously reported in BAC genomic clone RG054 D04 (Research Genetics) was used as a template, and PCR was performed with primers M452 (5'-GTACATACGGTGGACAAGCCTA-3')(SEQ ID NO:34) and M446 (5'- CATTCCCTCTCCCTTCACTGGATCCACATAGCC-3')(SEQ ID NO:35).

15 All PCR products were resolved by 1% agarose gel electrophoresis. Candidate bands were extracted from the agarose gel using the QIAquick Gel extraction kit from Qiagen followed by blunt end ligation into the pGEM-T-Vector (Promega) by standard procedures. (Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, 20 NY, 1989, which is incorporated by reference). Following bacterial transformation and growth of transformants, plasmids were purified using a QIAfilter plasmid kit from CLONTECH, and subjected to automated sequence analysis using either an ABI 373S or 377XL automated DNA sequencer (PE Biosystems).

Figure 9 shows the results of PCR amplification of the novel human 25 iPLA<sub>2</sub> sequence, iPLA<sub>2</sub>γ. Specifically, PCR was performed using human heart cDNA (0.5 ng; *lane 1* in Figure 9), a cDNA library prepared from human heart (*lane 2*), human skeletal muscle (*lane 3*), and a blank control (*lane 4*), as templates as described in detail above. PCR primer M444 was positioned at the 5'-end, and primer M449 positioned at the 3'-end of the iPLA<sub>2</sub>γ coding sequence, in 30 cycles of amplification

at 53°C for 30 seconds, 72°C for 2 minutes, and 94°C for 30 seconds. PCR products were analyzed on a 1% agarose gel and visualized using ethidium staining. Molecular size markers are shown at left in kb. PCR analysis gave rise to a single band, which was 2.4 kb in length, as indicated by the arrow.

5

#### EXAMPLE 2

This example illustrates the determination and characterization of the full length amino acid sequence of iPLA<sub>2</sub>γ, based on the PCR product described in Example 1, Figure 9.

First, the PCR product was cloned and the sequence analyzed. More specifically, the PCR product was subcloned into pGEM-T Vector and sequenced in both directions. Based on amino acid residue 1 being the initiator methionine, the message encoded a 782-amino acid polypeptide with a calculated molecular weight of 88,476.9. Contained within the sequence were an ATP binding motif at amino acid residues 449-45, and a lipase consensus sequence at amino acid residues 481-485, as well as multiple cAMP phosphorylation sites, PKC phosphorylation sites, CK2 phosphorylation sites, and a microbody C-terminal targeting sequence as determined by a Prosite pattern search (Hofmann et al., *Nucleic Acids Res.* 27: 215-19, 1999; Bucher, P. and Bairoch, A. *ISMB-94 Proceedings: 2<sup>nd</sup> International Conference on Intelligent Systems for Molecular Biology*, Menlo Park, CA, pp. 53-61, AAAI Press, Menlo Park, CA, 1994, which are incorporated herein by reference).

Figure 10 is a schematic representation of the strategy utilized for sequencing the PCR product encoding iPLA<sub>2</sub>γ. Size in nucleotides is indicated by the scale at top. Below the size scale is a schematic representation of the full-length iPLA<sub>2</sub>γ coding sequence, indicating the location of the ATP binding consensus sequence at nt 1345-1362, and lipase consensus sequence at nt 1441-1445. The arrows represent the direction and length of the sequences obtained from individual sequencing reactions. At the bottom is a schematic enlargement of a region of

sequencing differences between the iPLA<sub>2</sub>γ sequence as determined by the inventors, and the previously reported BAC clone sequence of a putative phospholipase.

As shown at the bottom of Figure 10, in the region between amino acid residues 351 and 358, the sequence analysis demonstrated ten putative differences between the iPLA<sub>2</sub>γ sequence as determined by the inventors, and the previously reported GenBank™ sequence. However, three pieces of information substantiate the integrity of the sequence determined by the inventors. First, rat clone UI-R-C0-hp-c-06--0-UI (accession number AA998901) EST sequence agreed in its entirety with the sequence identified by the inventors. Second, the inventors' sequencing of the region of difference between their iPLA<sub>2</sub>γ sequence and the previously reported GenBank™ sequence, in both directions from multiple different libraries, gave identical results. Third, sequencing of the original BAC clone in both directions produced identical results to those shown in Figure 10. Accordingly, it is believed that multiple errors are present in GenBank™ sequence RG054D04 in residues 351-358, and that the sequence shown in Figure 10 is correct.

To further analyze the deduced iPLA<sub>2</sub>γ amino acid sequence shown above in Figure 10, a Kyte-Doolittle hydrophobicity analysis was performed on the sequence. (Kyte, J. and Doolittle, R.F., *J. Mol. Biol.* 157:105-132, 1982, which is herein incorporated by reference). Figure 11 shows a hydropathy plot of the deduced amino acid sequence of human iPLA<sub>2</sub>γ. A window size of 17 amino acids was used. Negative values on the y-axis represent increasing hydrophobicity. Hydrophobicity analysis thus revealed that the putative iPLA<sub>2</sub>γ had two major hydrophobic domains, a first at the extreme putative N-terminus and a second centered near the lipase consensus sequence, at Ser<sup>483</sup>.

To determine whether the iPLA<sub>2</sub>γ PCR product represented the true 5'-end of the coding sequence, and to locate additional message sequence 5' of nt 122,761, 5'-RACE was performed using a reverse primer (M460) near the 5'-end of the 2.4 kb phospholipase A<sub>2</sub>γ PCR product, and a sense primer (AP1) to the adapter sequence flanking the cDNA template.

More specifically, for 5'-RACE, a 45-cycle program with steps at 58 °C for 30 seconds, 72 °C for 2 minutes, and 94 °C for 30 seconds per cycle was employed. Human heart Marathon-ready cDNA was used as a template (0.5 ng) and primer AP1 (CLONTECH) was paired with M460 (5'-

5 GAAAACCTTTGTAGACTGATGTGGCTTATCCTCCAG-3')(SEQ ID NO:36) to amplify products. Products were analyzed by electrophoresis utilizing a 1% agarose gel and visualized by ethidium bromide staining. PCR products were excised from the gel, purified with a QIAquick gel extraction kit, and subcloned into pGEM-T vector (Promega) for sequencing and alignment with the iPLA<sub>2</sub>γ sequence.

10 The full-length human iPLA<sub>2</sub>γ message sequence as determined using 5'-RACE includes a putative transcription initiation site, 5'-untranslated region, coding sequence, and 3'-untranslated region that together form a 3.4kb mature message. Thus, this maneuver extended the 5' sequence from the putative initiator methionine residue an additional 225 base pairs upstream. Because the 225-base pair

15 sequence contained stop codons in all three reading frames, it is believed that no additional coding regions are present in the 225-base pair sequence. The most 5' ATG site that is in frame with the calcium-independent phospholipase A<sub>2</sub>γ is located at nt 226. Additional in-frame ATG sites are located at nt 526, 589 and 886. Initiation of polypeptide synthesis at these potential methionine start sites would result in

20 polypeptides of 77, 74 and 63 kDa, respectively. At the 3'-end of the gene, a signal site for 3' poly(A) processing (AATAAA) was identified 757 nt 3' of the TGA stop signal. The actual cleavage site for poly(A) addition usually occurs 10-30 nt 3' of the poly(A) signal, and at this location, a CA is believed to be the preferred sequence immediately 5' to the cleavage site. Additionally, GU-rich or U-rich elements are also

25 typically found downstream of the poly(A) site. Since a CA dinucleotide occurs 35 nt 3' of the poly(A) signal sequence in iPLA<sub>2</sub>γ, and highly U-rich sequences occur at nucleotides 3339-3343 and at 3373-3392, the inventors have deduced that the likely point of poly(A) addition occurs following nucleotide 3372. Accordingly, these results identify a putative transcription initiation site, 5'-untranslated region, coding

sequence, and 3'-untranslated region that together form a 3.4 kb mature message for iPLA<sub>2</sub>γ.

To determine if the 3.4 kb message was the full-length or nearly full-length message, or if additional, as yet unidentified regions of the gene were transcribed to potentially serve a promoter function, Northern blot analysis of human iPLA<sub>2</sub>γ mRNA was performed on multiple tissues.

For Northern blot analysis, full-length of iPLA<sub>2</sub>γ amplified by PCR was prepared for use as a probe by radiolabeling with [<sup>32</sup>P]dCTP for one (1) hour at 37 °C in the presence of Ready-to-Go labeling beads (Amersham Pharmacia) according to the instructions provided by the manufacturer. The radiolabeled probe was purified by gel filtration employing a 1-ml Sepharose G-25 spin column. For Northern analysis, and MTN blot(CLONTECH0 containing 2μg of poly(A)<sup>+</sup> RNA/lane from human brain, heart, liver, lung, pancreas and placental tissue was prehybridized at 68 °C for 30 minutes in hybridization buffer, hybridized for one hour at 68 °C with radiolabeled iPLA<sub>2</sub>γ ( $2 \times 10^6$  cpm/ml), and washed in 2xSSC and 0.1% SDS twice for 30 minutes, followed by two washes with 0.1xSSC and 0.1% SDS for 40 minutes each at 50 °C as per the manufacturer's instructions. Hybridized sequences were identified by autoradiography for 16 hours.

Figure 12 shows the results of a Northern blot analysis of human iPLA<sub>2</sub>γ mRNA. The Northern blot was human mRNA obtained from the multiple tissues, and the tissue distribution of iPLA<sub>2</sub>γ mRNA thus examined by hybridization of the <sup>32</sup>P-labeled full-length iPLA<sub>2</sub>γ with approximately 2 μg of human poly(A)<sup>+</sup> mRNA, followed by autoradiography, as described above. *Lane 1* shows the results from heart, *lane 2* from brain, *lane 3* from placenta, *lane 4* lung, *lane 5* from liver, *lane 6* from skeletal muscle, *lane 7* from kidney, and *lane 8* from pancreas. The positions of RNA size markers are shown. Relative size in kb is indicated at left based on the mobility of the RNA standard ladder.

Northern blotting of human heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas mRNA demonstrated that each of these tissues possessed a 3.4 kb message that tightly bound to the full-length  $^{32}\text{P}$ -labeled probe. The largest amount of message was present in heart, followed by the placenta and skeletal muscle, with smaller amounts present in brain, kidney, pancreas, lung and liver. Within the limits of resolution of the Northern blotting technique, only a single band was identified. Thus, the results indicate that the message identified by the inventors and shown in Figure 12 is either full-length or nearly full-length. Multiple additional 5'-RACE reactions from multiple libraries did not identify any further sequence.

10

### EXAMPLE 3

This example illustrates analysis of the complete genomic organization of the iPLA<sub>2</sub> $\gamma$  gene. To determine the genomic organization of the full-length iPLA<sub>2</sub> $\gamma$  gene, an examination was undertaken of sequence upstream from the putative start site of the BAC genomic clone (GenBank™ accession number AC005058).

15

Examination of the iPLA<sub>2</sub> $\gamma$  sequence upstream from the putative transcription start site did not reveal the presence of either TATA box, nor CAAT box consensus sequences. The full-length message of iPLA<sub>2</sub> $\gamma$  was aligned with BAC genomic clone RG054D04 sequence to determine the location of intron/exon boundaries. Two intron/exon boundaries were then identified within the 5'-untranslated region of the iPLA<sub>2</sub> $\gamma$  sequence utilizing conventional AG/GT splicing rules.

20

Figure 13 is a schematic illustration of the human iPLA<sub>2</sub> $\gamma$  gene, deduced by determining the locations of intron/exon boundaries. Intron/exon boundaries of the iPLA<sub>2</sub> $\gamma$  gene are shown in scale (in kilobases). The eleven (11) exons of the gene are indicated as open boxes. Spaces between the exons represent the relative sizes of the ten (10) introns contained within the gene. Regions of the gene that correspond to the ATP binding, lipase and peroxisomal localization consensus sequences are indicated in exons 5, 6 and 11, respectively. The dashed box

enclosing exons 5-11 corresponds to previously identified exons in the BAC genomic clone (GenBank™ accession number AC005058). The boxes at the bottom indicate the nucleotide numbers corresponding to the original BAC genomic clone report, with the sizes of each exon in nucleotides and in amino acids shown within.

5 More specifically, exon 1 of the iPLA<sub>2</sub>γ gene is 96 nt in length, (nucleotides 133,299-133,394 of BAC genomic clone RG054D04) and is followed by a 4.5-kb intron. Exon 2 is 46 nt in length, (nucleotides 128,746-128,791 of BAC genomic clone RG054D04) and is followed by a 5.9-kb intron. The first candidate ATG start site occurs 84 nt downstream from the start of exon 3 (nucleotides 121,692-122,844 of BAC genomic clone RG054D04), which is 1151 nt in length and followed by a 139-nt intron 3. Exon 4 is 139 nt in length, (nucleotides 121,411-121,522 of BAC genomic clone RG054D04) and is followed by an 11.5-kb intron. Exon 5 begins the coding sequence previously reported in the GenBank™ BAC clone report, as indicated in Figure 13. Based on these findings, the iPLA<sub>2</sub>γ gene on chromosome 7 is 15 54 kb in size and contains 11 exons, ranging in size from 46 to 1151 nucleotides. Further, the results indicate that both the ATP binding motif (amino acid residues 449-454), and the lipase consensus sequence (amino acid residues 481-485) of the iPLA<sub>2</sub>γ gene require splicing of adjacent exons to form complete functional sequences. This splicing requirement distinguishes iPLA<sub>2</sub>γ from the iPLA<sub>2</sub>β, which contains its 20 functional ATP and lipase sites within a single exon.

Still further, these results show that the promoter region of the iPLA<sub>2</sub>γ gene contains neither a TATA box nor a CCAAT sequence within 400 nucleotides flanking the putative transcription start site. However, Tfsearch analysis reveals other promoter elements (e.g. several Sp1/GC boxes) that are located in the promoter 25 region, as well as several potential cap signals. One of the potential cap signals is located immediately upstream of the predicted transcription initiation site (i.e. at residues -6 to -13). TATA-less promoters are generally thought to typically respond to a variety of stimuli, with a range of transcription regulatory responses including differential expression during embryogenesis, tissue-specific distribution, and

regulation by either viral or pharmacologic stimuli. Many TATA-less genes are growth-regulated, so that low levels of gene expression are seen in non-growing cells but then expression up-regulated as cells proliferate. Thus, these results provide a foundation for studies in which the identified promoter region is fused to a reporter gene and subsequently dissected to determine important transcriptional regulatory elements by deletional mutagenesis.

To investigate the possible existence of iPLA<sub>2</sub>γ splice variants including alternative locations of intron/exon boundaries, further analysis of the iPLA<sub>2</sub>γ sequence upstream from the putative transcription start site of the BAC genomic clone was undertaken. Three alternative splice variants were discovered. Figure 2 is a schematic illustration of the three alternative splice variants of the iPLA<sub>2</sub>γ gene, deduced in this further examination. A region of variation, including exons 1, 2 and 3 as identified above, is shown. Labeling indicates the size of corresponding protein in kDa, and length in nucleotides (nt). Open boxes are noncoding regions, shaded regions are putative coding regions, and stippled lines represent intron splicing. The three splice variants included a first, “Gamma 1”, that includes exon 1, exon 2 and a portion of exon 3 in noncoding region, with the start site in exon 3. A second, “Gamma 2” variant, includes exon 1 and a portion of exon 3 in noncoding region, but excludes exon 2 altogether. A third, “Gamma 3” variant, includes a new potential ATG start site in exon 1, and thus a portion of exon 1, all of exon 2 and a truncated exon 3 in coding region.

#### EXAMPLE 4

To determine the molecular weight of the protein(s) translated by the iPLA<sub>2</sub>γ message, the 2.4 kb PCR product as described above was expressed in an *in vitro* reticulocyte lysate translation system, and the molecular weights of the protein products determined.

For *in vitro* translation, a full-length iPLA<sub>2</sub>γ construct in pcDNA1.1 (1μg) was used in a coupled transcription/translation rabbit reticulocyte translation

lysate system (Promega) with RNA synthesis from the T7 promoter of pcDNA1.1 using T7 RNA polymerase and translation in the presence of 20  $\mu$ Ci of [ $^{35}$ S] methionine for 90 minutes according to the manufacturer's instructions. More specifically, the full-length iPLA<sub>2</sub> $\gamma$  PCR product was cloned into pcDNA1.1 vector so that the T7 promoter region of pcDNA1.1 was upstream from the iPLA<sub>2</sub> $\gamma$  sequence.  
5 For coupled *in vitro* transcription/translation, RNA was synthesized from 1  $\mu$ g of iPLA<sub>2</sub> $\gamma$ -pcDNA1.1 in the presence of T7 RNA polymerase. Translation of RNA in the rabbit reticulocyte lysate system was performed in the presence of [ $^{35}$ S]methionine, and following translation, 5  $\mu$ l of labeled product was boiled for two  
10 minutes in SDS loading buffer. Translated, radiolabeled protein products were then resolved by SDS gel electrophoresis and visualized by autoradiography.

Figure 14 shows the resolution by gel electrophoresis and visualization by autoradiography of two radiolabeled protein products of iPLA<sub>2</sub> $\gamma$  *in vitro* translation. . *In vitro* translated product corresponding to iPLA<sub>2</sub> $\gamma$  is shown at left and indicated by "math>" $\gamma$ ", and a negative control indicated by "ctl" is shown at right. More specifically, Figure 14 shows the resolution a first product corresponding to a molecular mass of approximately 77 kDa and a second corresponding to a molecular mass of approximately 63 kDa. Sizes of molecular weight standards in kDa are indicated at left.  
15

20 The first radiolabeled protein product of about 77 kDa corresponds to translation initiation at methionine residue 101 of the full-length 88 kDa. The second radiolabeled protein product of about 63 kDa corresponds to translation initiation at methionine residue 221 of the full-length iPLA<sub>2</sub> $\gamma$ .

#### EXAMPLE 5

25 To compare the results of *in vitro* translation as described in Example 4, with translation in an intact eukaryotic cell, the translation of 2.4 kb iPLA<sub>2</sub> $\gamma$  in Sf9 cells was investigated.

This example thus illustrates the determination of the molecular weights of the two identified protein products of the iPLA<sub>2</sub>γ gene as expressed in an intact eukaryotic cell, that the observed products correspond to results obtained in the *in vitro* translation as described in Example 4, and that iPLA<sub>2</sub>γ protein products are present predominantly in the cell membrane.

Expression of iPLA<sub>2</sub>γ in an intact eukaryotic system was evaluated using cultured *Spodoptera frugiperda* (Sf9) cells. Sf9 cells have been widely used to express recombinant proteins as a host cell in the baculovirus expression system. (See e.g. Liu et al., *J. Immunol.* 156:3292-300, 1996). It is believed that the translational elements of Sf9 cells exhibit a high degree of homology with mammalian translational elements. (See e.g. Sakahira et al., *J. Biol. Chem.* 274:15740-4, 1999; Kimball et al., *J. Biol. Chem.* 273:12841-5, 1998; Gu et al., *Biochim. Biophys. Acta* 1399:1-9, 1998). Sf9 cells were grown and infected with wild-type or recombinant baculovirus containing human phospholipase A<sub>2</sub>γ cDNA as described in detail in Wolf, M.J. and Gross, R.W., *J. Biol. Chem.* 271:30879-85, 1996, which is herein incorporated by reference. Culture of Sf9 cells involved, in brief, placing Sf9 cells in growth medium in 100-ml spinner flasks equipped with a magnetic spinner. The rotation speed of the magnetic spinner was set at about 80 rpm, which is believed to be especially suitable for optimizing growth of Sf9 cells. The growth medium included Grace's medium supplemented with Yeastolate, Lactalbumin, 1% Antimycotic (all from Sigma), 10% fetal bovine serum and 1% Plutonic F-68 surfactant. Sf9 cells at a concentration of 1x10<sup>6</sup> cells/ml were prepared in 50 ml of the growth medium and incubated at 27°C for one (1) hour prior to infection with either wild-type baculovirus or recombinant baculovirus containing human phospholipase A<sub>2</sub>γ cDNA. After 48 hours, cells were repelleted by centrifugation, resuspended in ice-cold phosphate-buffered saline, and repelleted. All subsequent operation were performed at 4°C. The supernatant was decanted, and the cell pellet was resuspended in 5 ml homogenization buffer (25 mM imiazole, pH 8.0, 1 mM EGTA, 1mM dithiothreitol, 0.34 M sucrose, 20 MM transepoxysuccinyl-L-leucylamido-(4-guanidino) butane, and 2μg/ml leupeptin. Cells were lysed at 0°C by sonication (twenty (20) one-second bursts utilizing a Vibra-cell

sonicator at a 30% output) and centrifuged at 100,000 x g for one (1) hour. The supernatant containing predominantly cytosol was saved, and the membrane pellet was washed with homogenization buffer and resuspended using a Teflon homogenizer in 6 ml of homogenization buffer. After a brief sonication (ten (10) one-second bursts), the mixture was subjected to re-centrifugation at 100,000 x g for one (1) hour. After removal of the supernatant, the membrane pellet was resuspended in 1 ml homogenization buffer using a Teflon homogenizer and subsequently sonicated at 0°C for five (5) one-second bursts.

The 2.4-kb message encoding iPLA<sub>2</sub>γ as identified was inserted into the Sf9 cell vector pFASTBAC. Spinner cultures of Sf9 cells were infected with either the wild-type pFASTBAC (“Ctl”) or pFASTBAC containing the 2.4-kb message (“γ”). At 48 hours post-infection, the cells were collected and cytosolic (“Cyto”) and membrane (“Memb”) fractions prepared as described above.

Sf9 cell cytosol and membrane fractions were loaded on a 10% polyacrylamide gel, resolved by SDS polyacrylamide gel electrophoresis, transferred to a polyvinylidene difluoride membrane, by electroelution in 10 mM CAPS, pH 11, containing 10% methanol. Dry powdered milk (5% w/v) in 20 mM Tris-HCl, pH 7.4, containing 137 mM NaCl and 0.1% Tween 20 was used to block non-specific binding sites before incubation with the primary antibody, immunoaffinity-purified antibody directed against iPLA<sub>2</sub>γ, prepared as described below. Secondary antibody (anti-rabbit IgG horseradish peroxidase conjugate) was incubated with the blot for 1 hour and immunoreactive bands were visualized by ECL.

Immunoaffinity-purified polyclonal antibody directed against iPLA<sub>2</sub>γ was prepared by immunizing rabbits with the iPLA<sub>2</sub>γ synthetic peptide CENIPLDESRNEKLDQ (SEQ ID NO:37). This peptide (G3, 4 mg), dissolved in minimal volume of dimethylsulfoxide, was conjugated to maleimide-activated keyhole limpet hemocyanin (KLH, 2 mg) in 200 μl of 83 mM sodium phosphate, 0.9 M NaCl, and 0.1 mM EDTA at 22 °C for two hours. After extensive dialysis against 83 mM sodium phosphate containing 0.9 mM NaCl, a 1:1 emulsion was made with

the peptide-KLH conjugate and Freund's complete adjuvant. This emulsion was then injected subcutaneously into two anaesthetized New Zealand white rabbits. Two booster injections of a 1:1 emulsion of the peptide-KLH aonjugate and Freund's incomplete adjuvant were given two and four weeks after the initial immunization.

5      Serum was then A peptide affinity column was generated by coupling the iPLA<sub>2</sub>γ synthetic peptide to a thiopropyl-Sepharose (Amersham-Pharmacia) resin in the presence of 100 mM sodium citrate, pH 4.5. The resin-peptide suspension was mixed by inversion overnight at 22 °C. Coupling efficiency was monitored by the displacement of the 2-pyridyl sulfide groups as 2-thiopyridone through

10     spectrophotometric monitoring at 343 nm. Before chromatography, the resin-peptide suspension was equilibrated with 10 mMTris-HCl, pH 7.5 in an Econo-pac column (BioRad) by gravity flow. Serum containing the anti the iPLA<sub>2</sub>γ antibodies was diluted 1:10 (v/v) with 10 mM Tris-HCl, pH 7.5 and then applied to the peptide affinity column by gravity flow. The diluted serum was then re-applied twice to the

15     column to assure binding of the antibody to the column. After washing the column extensively with 10 mM tris-HCl, pH 7.5 containing 500 mM NaCl, bound anti-iPLA<sub>2</sub>γ antibody was eluted from the column with 100 mM glycine, pH 2.5 and the immediately neutralized with 100 mM Tris-HCl, pH 9.0. The antibody was then concentrated using Centricon-10 (Americon) centrifugal filter devices and stored at 40

20     °C until use.

Figure 15 shows the results of Western analysis of iPLA<sub>2</sub>γ expression in Sf9 cells, and confirm in an intact eukaryotic system the identification of translation initiation sites at methionine residues 101 and 221 as identified in the *in vitro* system as described in Example 4. The results as shown in Figure 15 are typical of three independent experiments. Specifically, Western analysis of membrane fractions from Sf9 cells infected with vector harboring iPLA<sub>2</sub>γ ("γ Memb") demonstrated the presence of two major bands corresponding to molecular masses of 77 and 63 kDa. However, no such products were present in membrane fractions from Sf9 cultures infected with wild-type virus ("Ctl Memb"). In contrast, cytosolic fractions from control or iPLA<sub>2</sub>γ-transfected Sf9 cells did not contain any detectable immunoreactive

protein. Collectively, these results support the existence of two translation initiation start sites at methionine residues 101 and 221.

#### EXAMPLE 6

5 To determine whether iPLA<sub>2</sub>γ translation products as described in Example 5 are biologically active, a phospholipase enzyme activity analysis was undertaken of Sf9 cells infected with recombinant baculovirus encoding iPLA<sub>2</sub>γ. This example demonstrates that iPLA<sub>2</sub>γ translation products are biologically active and more specifically, are catalysts of cleavage of the *sn*-2-fatty acid of choline  
10 glycerophospholipids

Briefly, Sf9 cells were infected with either wild-type baculovirus (□) or baculovirus encoding human iPLA<sub>2</sub>γ (●), as described in Example 5. Cytosolic and membrane fractions of the infected Sf9 cells were prepared as described above.  
15 Phospholipase A<sub>2</sub> activity was assessed as follows. Membrane fractions from control cells or cells expressing iPLA<sub>2</sub>γ were incubated with 40 μM L-α-1-palmitoyl-2-[1-<sup>14</sup>C]oleoyl phosphatidylcholine in 100mM Tris-Hac, pH 8.0, containing 1 mM EGTA at 37 °C. Aliquots of the reaction were removed at the indicated times, and the amount of [1-<sup>14</sup>C]oleic acid released was quantified as described above. Specifically, the release of *sn*-2-fatty acid from 1-hexadecanoyl-2-[1-<sup>14</sup>C]octadec-9'-enoyl-*sn*-glycero-3-phosphocholine was determined as a function of time.  
20

Figure 16 is a graph showing an initial rate analysis of phospholipase activity in Sf9 cells infected with recombinant baculovirus encoding iPLA<sub>2</sub>γ. The results shown in Figure 16 are representative of three independent experiments.

25 Membrane fractions from cells infected with vector harboring the iPLA<sub>2</sub>γ insert released fatty acid from the *sn*-2-position of phosphatidylcholine approximately 10-fold faster than from membrane fractions prepared control cells infected with wild-type vector. Liberation of *sn*-2-radiolabeled fatty acid was nearly

linear for 2 minutes at a velocity of approximately 0.3 nmol/mg-min. Phospholipase A<sub>2</sub> activity was entirely calcium independent in the range of 0-10 mM and demonstrated a pH optimum at pH 8.0 (not shown), which is at or near physiologic pH.. In contrast, phospholipase A<sub>2</sub> activities in cytosolic fractions of cells infected with wild-type vector and from cells infected with vector harboring the iPLA<sub>2</sub> $\gamma$  insert were found to be similar (not shown).

To determine the substrate selectivity of the phospholipase A<sub>2</sub> activity demonstrated in Sf9 cells infected recombinant baculovirus encoding iPLA<sub>2</sub> $\gamma$ , multiple alternative phospholipase A<sub>2</sub> substrates were tested. Membrane fractions from both groups of cells were incubated in 100 mM Tris-HAc, pH 8.0, containing 1 mM EGTA for 2 minutes at 37 °C in the presence of either 40  $\mu$ M L- $\alpha$ -1-dipalmitoyl-2-[1-<sup>14</sup>C]phosphatidylcholine (“PPPC”), L- $\alpha$ -1-palmitoyl-2-[1-<sup>14</sup>C]oleoyl phosphatidylcholine (“POPC”), L- $\alpha$ -1-palmitoyl-2-[1-<sup>14</sup>C]linoleoyl phosphatidylcholine (“PLPC”), or L- $\alpha$ -1-palmitoyl-2-[1-<sup>14</sup>C]arachidonoyl phosphatidylcholine (“PAPC”). Reactions were terminated by butanol extraction, and radiolabeled fatty acids were resolved by TLC and quantitated by scintillation spectrometry.

Figure 17 is a substrate selectivity profile of iPLA<sub>2</sub> $\gamma$  phospholipase A<sub>2</sub> activity in Sf9 cells infected recombinant baculovirus encoding iPLA<sub>2</sub> $\gamma$ . Panel A shows the results of phospholipase A<sub>2</sub> activity analysis from Sf9 cells infected with either wild-type baculovirus (stippled bars) or recombinant baculovirus encoding iPLA<sub>2</sub> $\gamma$  (solid bars). The results are representative of three independent experiments. Thus, incubation of membrane fractions containing iPLA<sub>2</sub> $\gamma$  with phospholipids containing three distinct types of unsaturated fatty acids at the *sn*-2-position (oleic, linoleic, and arachidonic acids) gave similar specific activities that were each 6-10 times greater than activities manifest in membrane preparations derived from cells infected with wild-type vector

Figure 17, Panel B shows the results of further phospholipase A<sub>2</sub> activity analyses undertaken to identify the initial site of hydrolysis of phospholipids

by iPLA<sub>2</sub> $\gamma$ . Membranes derived from Sf9 infected with either wild-type baculovirus (stippled bars) or recombinant baculovirus encoding iPLA<sub>2</sub> $\gamma$  (solid bars) were incubated with either 40  $\mu$ M L- $\alpha$ -1-palmitoyl-2-[1-<sup>14</sup>C]oleoyl phosphatidylcholine (“POPC”), or 40  $\mu$ M synthetic radiolabeled 1-*O*-(Z)-hexadec-1'-enyl-2-[9,10-<sup>3</sup>H]octadec-9'-enoyl-*sn*-glycero-3-phosphocholine (“plasmenyl-PC”), under 5 incubation conditions as described for Panel A. Plasmenyl choline has a relatively enzymatically resistant vinyl ether linkage at *sn*-1.

Panel B of Figure 17 shows that the rate of hydrolysis using plasmenyl choline was similar to that using *sn*-2-[1-<sup>14</sup>C]phosphatidylcholines, thus supporting 10 the conclusion that hydrolysis of substrate by iPLA<sub>2</sub> $\gamma$  occurs predominantly at the *sn*-2-position. Therefore, iPLA<sub>2</sub> $\gamma$  gene products are catalysts of cleavage of the *sn*-2-fatty acid of choline glycerophospholipids.

#### EXAMPLE 7

To establish iPLA<sub>2</sub> $\gamma$  as a member of the calcium-independent 15 phospholipase A 2 family, the inhibition of the phospholipase A<sub>2</sub> activity of iPLA<sub>2</sub> $\gamma$  by (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one (BEL) was studied.

(E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one (BEL) has previously been shown to be a powerful and irreversible mechanism-based 20 inhibitor of myocardial cytosolic and membrane-associated iPLA<sub>2</sub>, with nearly complete inhibition of myocardial cytosolic membrane-associated iPLA<sub>2</sub> at concentrations of approximately 2-5  $\mu$ M. (Hazen et al., *J. Biol. Chem.* 266:7227-32, 1991; Zupan et al., *J. Med. Chem.* 36: 95-100, 1991; Gross et al., *Biochemistry* 32:327-36, 1993; Ramanadham et al., *Biochemistry* 32:337-46, 1993, which are herein 25 incorporated by reference).

Briefly, Sf9 cells were infected with either wild-type baculovirus (□) or baculovirus encoding human iPLA<sub>2</sub> $\gamma$  (●), as described in Example 5. Membrane fractions of the infected Sf9 cells were prepared as described above, and then

incubated for three minutes at room temperature in 100 mM Tris-HAc, pH 8.0, containing 1mM EGTA, with varying concentrations of BEL, or ethanol vehicle, as indicated along the x-axis. L- $\alpha$ -1-palmitoyl-2-[1-<sup>14</sup>C]oleoyl phosphatidylcholine (40  $\mu$ M final concentration) in ethanol was then added to each reaction, followed by 5 incubation at 37 °C for two minutes. Released [1-<sup>14</sup>C]oleic acid was quantitated as described above.

Figure 18 is a graph showing inhibition of the phospholipase A<sub>2</sub> activity of iPLA<sub>2</sub> $\gamma$  by (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one (BEL). The results shown in Figure 18 were representative of three 10 independent experiments.

As shown in Figure 18, preincubation of membranes harboring iPLA<sub>2</sub> $\gamma$  with 5  $\mu$ M BEL for three minutes prior to the addition of substrate resulted in the inhibition of approximately 70% of iPLA<sub>2</sub> $\gamma$  phospholipase A<sub>2</sub> activity. The IC<sub>50</sub> for BEL inhibition of iPLA<sub>2</sub> $\gamma$  was approximately 3  $\mu$ M. Thus, the results establish that 15 BEL is an effective inhibitor of iPLA<sub>2</sub> $\gamma$ .

Previous work has characterized iPLA<sub>2</sub> activity in certain tissues, as well as a calcium-facilitated phospholipase A<sub>2</sub> $\gamma$ . Specifically, prior studies have identified iPLA<sub>2</sub> activity in cytosolic and membrane fractions of canine and human myocardium. (Wolf, R.A. and Gross, R.W., *J. Biol. Chem.* 260:7295-303, 1984; Hazen, S.L. and Gross, R.W., *Circ. Res.* 70:486-95, 1992, which are herein incorporated by reference). Additional studies have demonstrated an increase in membrane-associated, BEL-inhibitable iPLA<sub>2</sub> activity during myocardial ischemia or hypoxia. (Hazen et al., *J. Biol. Chem.* 266:5629-33, 1991; Ford et al., *J. Clin. Inv.* 88:331-35, 1991; McHowat J. and Creer, M.H., *Lipids* 33:1203-12, 1998; McHowat et al., *Am. J. Physiol.* 274:C1727-37, 1998, which are herein incorporated by 20 reference). It has also been proposed that increased myocardial iPLA<sub>2</sub> activity during ischemia contributes to ventricular arrhythmias and hemodynamic dysfunction through the production of lysophospholipids and arachidonic acid, each of which has potent electrophysiological effects. (Wolf, R.A and Gross, R.W., *supra*; Gross, *Trends* 25

*Cardiovasc. Med.* 26:115-21, 1992; and Gross, *Biochem. Soc. Trans.* 26:345-49, 1984, which are herein incorporated by reference).

A calcium-facilitated phospholipase A<sub>2</sub>γ shares homology with the catalytic domain of calcium-facilitated phospholipase A2α and has been cloned and expressed. Northern analysis has demonstrated the presence of calcium-facilitated phospholipase A<sub>2</sub>γ message in skeletal and heart muscle, and cloning and expression of calcium-facilitated phospholipase A<sub>2</sub>γ in Sf9 cells has confirmed the membrane localization and calcium-independence of calcium-facilitated phospholipase A<sub>2</sub>γ. (Underwood et al., *J. Biol. Chem.* 273:21926-32, 1998 which is herein incorporated by reference). However, calcium-facilitated phospholipase A<sub>2</sub>γ is not inhibited by BEL at <50 μM [BEL] (C.M. Jenkins, D.J. Mancuso and R.W. Gross, manuscript in preparation) and is therefore clearly distinguishable from iPLA<sub>2</sub>γ, which is subject to potent inhibition by BEL as shown in Figure 19. In contrast, the large majority of iPLA<sub>2</sub> activity from ischemic hearts or hypoxic myocytes in culture is membrane-associated and exquisitely sensitive to BEL inhibition. Accordingly, the inventors herein have succeeded in identifying iPLA<sub>2</sub>γ as a likely polypeptide for catalyzing the increase in ischemia-induced iPLA<sub>2</sub> activity. Further, the results suggest that the peroxisomal compartment is a source of regulatory and potentially arrhythmogenic eicosanoid metabolites and lysophospholipids.

20

#### EXAMPLE 8

To determine whether iPLA<sub>2</sub>γ expression is subject to translational control, multiple iPLA<sub>2</sub>γ truncation mutants were prepared and their expression in Sf9 cells studied.

25

To prepare truncated iPLA<sub>2</sub>γ constructs in pFASTBAC, PCR primers containing appropriate restriction sites for cloning were used, and performed as described above. For example, the original full-length 88 kDa construct was used as a template in PCR with a sense primer annealing at nt 650-676 paired with reverse primer M458 (5'-GCATAGCATGCTCACATTGAAAAGAATGCAAGTCC-3')

(SEQ ID NO:38) to create a truncated iPLA<sub>2</sub>γ (63kDapF) with a methionine start site corresponding to amino acid 221 in the full-length protein. Expression of this construct in the baculovirus system as described above resulted in a 63 kDa recombinant protein. A second construct was created with a start site corresponding to methionine 122 to produce a 74kDa recombinant protein. Additional constructs were also prepared as described above to produce N-terminal truncated recombinant proteins of approximately 77, 70 and 66kDa that were used in additional studies of translational inhibition as described below in Example 9 . Further, the same methods were used to for segments of iPLA<sub>2</sub>γ 5' sequence ranging between 15-663 nt which were inserted 5' of the insert sequence in 63kDapF to identify potential sequences involved in translational regulation, as described below in Example 10.

The expression of the 63 kDa and the 74 kDa truncation mutants were studied in Sf9 cells using the expression system as described above. Cytosolic and membrane fractions were obtained as described above, and a Western analysis performed on the polypeptide products products of the 63 kDa and 74 kDa truncation mutants of iPLA<sub>2</sub>γ, as expressed in cytosolic and membrane fractions prepared from Sf9 cells.

Figure 19 shows the results of the Western analysis. The wild-type 88 kDa protein is indicated by iPLA<sub>2</sub><sup>1</sup>γ. Both cytosolic and membrane fractions ("63 kDa iPLA<sub>2</sub>γ Cyto" and "63 kDa iPLA<sub>2</sub>γ Memb", respectively) from Sf9 cells infected with vector harboring truncation mutants coding the 63 kDa product of iPLA<sub>2</sub>γ, demonstrated the presence of major bands corresponding to molecular mass of 63 kDa, though to a lesser extent in the cytosolic fraction. However, analysis of both cytosolic and membrane fractions ("74 kDa iPLA<sub>2</sub>γ Cyto" and "74 kDa iPLA<sub>2</sub>γ Memb", respectively) from Sf9 cells infected with vector harboring truncation mutants coding the 74 kDa product of iPLA<sub>2</sub>γ, demonstrated greatly decreased amounts of product in comparison to that expressed using the 63 kDa truncation mutant. Similarly, analysis of both cytosolic and membrane fractions ("iPLA<sub>2</sub><sup>1</sup>γ Cyto" and "iPLA<sub>2</sub><sup>1</sup>γ Memb", respectively) from Sf9 cells infected with vector harboring

truncation mutants coding the iPLA<sub>2</sub><sup>1</sup><sub>γ</sub>(i.e. wild-type 88 kDa protein), demonstrated little or no expressed product in comparison to that expressed using the 63 kDa truncation mutant. Collectively these results support the existence of a sequence or sequences involved in translation inhibition. Further, such sequences can be localized to the stretch of sequence representing the difference between the 63 kDa truncation mutant and the 74 kDa truncation mutant.

#### EXAMPLE 9

To more precisely localize the sequence involved in translational inhibition of iPLA<sub>2</sub><sub>γ</sub> multiple constructs were prepared according to the methods described above.

Briefly, each construct tested included the 63 kDa truncation mutant as described above, plus one of the truncation mutants. Specifically then the first construct included the 63 kDa truncation mutant plus the 63 kDa truncation mutant, the second construct included the 63 kDa truncation mutant plus the 66 kDa truncation mutant, the third construct included the 63 kDa truncation mutant plus the 70 kDa truncation mutant, the fourth construct included the 63 kDa truncation mutant plus the 74 kDa truncation mutant, the fifth construct included the 63 kDa truncation mutant plus the 77 kDa truncation mutant, and the sixth construct included the 63 kDa truncation mutant plus the full-length 88 kDa truncation mutant, all prepared as described above.

Expression of each construct in the baculovirus system was then studied in Sf9 cells, using the expression and Western analysis methods as described above. Figure 20 is a schematic illustration of the results of Western analysis of polypeptide products of each construct as expressed in Sf9 cells. Western analysis of both cytosolic and membrane fractions from Sf9 cells infected with vector harboring truncation mutants coding the 63 kDa + 63 kDa product of iPLA<sub>2</sub><sub>γ</sub>, demonstrated the expression of an immunoreactive band at 63 kDa. . Similarly, Western analysis of both cytosolic and membrane fractions from Sf9 cells infected with vector harboring

truncation mutants coding the 63 kDa + 66 kDa product of iPLA<sub>2</sub>γ, and those infected with vector harboring truncation mutants coding the 63 kDa + 70 kDa product, all demonstrated the expression of an immunoreactive band at 63 kDa. However, analysis of both cytosolic and membrane fractions from Sf9 cells infected with vector harboring truncation mutants coding the 63 kDa + 74 kDa product of iPLA<sub>2</sub>γ, demonstrated decreased immunoreactivity relative to those including the 63 kDa, 66 kDa or 70 kDa truncation mutants. Further, no immunoreactive band was detectable from cells containing the 77 kDa truncation mutant or the 88 kDa wild-type sequence. Thus, these results indicate translational inhibition by a sequence contained within the 77 kDa truncation mutant but not present in the 66 kDa or 70 kDa truncation mutants..

#### EXAMPLE 10

To further identify and locate the sequences involved in translational inhibition of iPLA<sub>2</sub>γ, the effect on translation of several iPLA<sub>2</sub>γ 23-mer sequences 5' of the 63 kDa sequence was studied.

Briefly, sequences from iPLA<sub>2</sub>γ were inserted by ligation of 15-23-mer annealed phosphorylated oligonucleotide pairs 5' of full-length luciferase coding sequence which was cloned into pFASTBAC via NotI/XbaI restriction sites. Luciferase activity of recombinant protein produced in the Sf9 system was then measured using the Luciferase Assay System of Promega. (Wood, K.V., (1991) In: *Bioluminescence and Chemiluminescence: Current Status*, Stanley, P. and Kricka, L. eds., John Wiley and Sons, Chichester, NY, 543; and *Luciferase Assay System Technical Bulletin*, #TB101, Promega Corporation, 1996, which are herein incorporated by reference). Figure 21 is a schematic diagram showing ligation of 23-mer iPLA<sub>2</sub>γ sequence to luciferase coding sequence and cloned into pFASTBAC.

Figure 22 is a schematic representation of the location of the 23-mer sequences studied. Schematic representations of the the 74 kDa protein product of iPLA<sub>2</sub>γ, as well as the 70kDa sequence, are shown at the top for comparison. "1/2", "3/4", "5/6", and "7/8" each indicate successive 23-mer DNA sequences taken from

coding region representing the difference between the sequences for a 70 kDa iPLA<sub>2</sub> $\gamma$  protein and the 74 kDa protein. The numbers 1-8 indicate the primers that were used to amplify each 23-mer piece. Constructs were prepared by fusing luciferase coding sequence to a one of the four alternative 23mer sequences from iPLA<sub>2</sub> $\gamma$ , and to the baculovirus promoter. Four alternative constructs, each containing one of the four different 23mer sequences from the 74 kDa iPLA<sub>2</sub> $\gamma$  truncation mutant, were prepared and then expressed in Sf9 cells as described above. After 48 hours allowed for expression, cell extracts were prepared and then tested for level of expression using the luciferase assay system as described in detail above.

Figure 23 shows the phosphorylated oligo pairs for sequence between nucleotide 364-455 that is involved in translation inhibition of iPLA<sub>2</sub> $\gamma$  in the lucifrease expression system, thus identifying four pairs, "1/2", "3/4", "5/6", and "7/8" which each indicate successive 23-mer DNA sequences taken from coding region representing the difference between the sequences for a 70 kDa iPLA<sub>2</sub> $\gamma$  protein and the 74 kDa protein.

Figure 24 is a bar graph showing luciferase assay results of the expression of three of the four different iPLA<sub>2</sub> $\gamma$  constructs. The graph plots relative light units (RLU) emitted for each of three constructs containing a different 23mer sequence from iPLA<sub>2</sub> $\gamma$  74 kDa truncation mutant, as described above. The first construct contained the 23-mer sequence identified as "1/2" on the x-axis, the second construct, contained the 23-mer sequence identified as "5/6" on the x-axis, and the third construct contained the 23-mer identified as "7/8" on the x-axis. The 3/4 sequence did not amplify. The results, including little or no expression of the construct containing the 1/2 sequence, thus show that at least a portion of 1/2 is involved in translational inhibition of iPLA<sub>2</sub> $\gamma$ . In contrast, the construct containing 5/6 resulted in a relatively high level of expression of iPLA<sub>2</sub> $\gamma$ , showing 5/6 is unlikely to be involved in translational inhibition. The results for the third construct containing 7/8 showed an intermediate level of expression that was not significantly different from the 5/6 construct. Thus, 7/8 is not likely to be involved in translational inhibition of iPLA<sub>2</sub> $\gamma$ . Thus, these results show that iPLA<sub>2</sub> $\gamma$  is subject to translational

inhibition by the 1/2 23-mer piece taken from coding region representing the difference between the sequences for a 70 kDa iPLA<sub>2</sub> $\gamma$  protein and the 74 kDa protein.

All references cited in this specification are hereby incorporated by reference. The discussion of the references herein is intended to summarize the assertions made by their authors and no admission is made as to the accuracy or pertinency of the cited references or that any reference is material to patentability.

While the invention has been described in terms of various specific embodiments in the examples, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the claims which follow.

10

## WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising a polynucleotide encoding a phospholipase A<sub>2γ</sub> polypeptide.
2. An isolated nucleic acid molecule according to claim 1, wherein said phospholipase A<sub>2γ</sub> polypeptide catalyzes cleavage of fatty acids from the *sn*-2-position of phospholipids.  
5
3. An isolated nucleic acid molecule according to claim 2 wherein said polynucleotide encodes a sequence as set forth in SEQ ID NO:1 or SEQ ID NO:2.
4. A vector comprising a nucleic acid molecule according to claim 1.
5. A cell transformed or transfected with a vector according to claim 4.  
10
6. An isolated nucleic acid molecule comprising a fragment of a polynucleotide encoding a phospholipase A2<sub>γ</sub> wherein said fragment specifically hybridizes with a sequence as set forth in SEQ ID NO:5 or SEQ ID NO:6.
7. An isolated nucleic acid comprising a polynucleotide having at least about 90% identity with SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6.  
15
8. An isolated nucleic acid according to claim 7 comprising SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6.
9. An antisense sequence which specifically hybridizes to SEQ ID NO:2, or SEQ ID NO:3 .
10. An isolated polypeptide comprising a phospholipase A2<sub>γ</sub>.  
20
11. An isolated polypeptide according to claim 10 which catalyzes cleavage of fatty acids from the *sn*-2-position of phospholipids.
12. An isolated polypeptide according to claim 11 which has at least 90% identity with SEQ ID NO:1 or SEQ ID NO:2.  
25
13. An isolated polypeptide according to claim 12 comprising SEQ ID NO:1 or SEQ ID NO:2.
14. An isolated polypeptide according to claim 12 which is a conservatively substituted variant of SEQ ID NO:1 or SEQ ID NO:2.
15. An antibody capable of binding to a phospholipase A2<sub>γ</sub> according to claim  
10.

16. A method of treating inflammation in a patient, said method comprising decreasing calcium-independent phospholipase A<sub>2</sub>γ activity in the patient.

17. A method according to claim 16 wherein the patient suffers from Alzheimer's disease, myocardial ischemia, or myocardial infarction.

5       18. A method according to claim 17 comprising administering to the patient a phospholipase A<sub>2</sub>γ translational repressor molecule.

19. A method according to claim 17 comprising administering to the patient an antisense sequence which specifically hybridizes to SEQ ID NO:3 or SEQ ID NO:4 .

10      20. A method of increasing fatty acid utilization in a patient in need thereof, said method comprising increasing iPLA<sub>2</sub>γ activity in the patient.

21. A method according to claim 20 wherein the patient suffers from diabetes or obesity.

22. A method according to claim 21 comprising administering to the patient a substance which blocks translational repression of iPLA<sub>2</sub>γ expression.

15      23. A method according to claim 21 comprising administering to the patient an iPLA<sub>2</sub>γ polypeptide as set forth in SEQ ID NO:1, SEQ ID NO:2 or a conservatively substituted variant thereof or administering a polynucleotide encoding said iPLA<sub>2</sub>γ polypeptide.

20      24. A method for measuring activity of a phospholipase A<sub>2</sub>γ polypeptide of cells in a biological sample, said method comprising introducing into the sample a phospholipid substrate for cleavage of fatty acids by the phospholipase A<sub>2</sub>γ , wherein the phospholipase A<sub>2</sub>γ cleaves fatty acid from the *sn*-2-position of the phospholipid substrate and measuring cleavage of the phospholipid substrate, wherein measuring cleavage of the phospholipid substrate comprises quantifying the release of fatty acid from the substrate.

25      25. An assay method for identifying substances which modulate iPLA<sub>2</sub>γ expression in a cell, said method comprising contacting a candidate substance with cells comprising a promoter sequence operably linked to an iPLA<sub>2</sub>γ repressor binding site and a reporter gene and measuring expression of the reporter gene.

30      26. A method according to claim 25 wherein said repressor binding site comprises SEQ ID NO:7.

27. A method according to claim 26 wherein said reporter gene encodes an enzyme capable of being detected by a colorimetric, fluorimetric or luminometric assay.

5        28. A method according to claim 27 wherein said reporter gene encodes a luciferase.

29. A method according to claim 26 wherein the promoter sequence is a baculovirus promoter sequence.

30. A method according to claim 26 wherein the cells are Sf9 cells.

10      31. A genetically engineered cell capable of identifying substances which modulate iPLA<sub>2Y</sub> expression in a cell, said cells comprising a promoter operably linked to an iPLA<sub>2Y</sub> repressor binding site and a reporter gene.

32. A genetically engineered cell according to claim 31 wherein said repressor binding site comprises SEQ ID NO:7.

15      33. A genetically engineered cell according to claim 32 wherein said reporter gene encodes an enzyme capable of being detected by a colorimetric, fluorimetric or luminometric assay.

34. A genetically engineered cell according to claim 33 wherein said reporter gene encodes a luciferase.

20      35. A genetically engineered cell according to claim 32 wherein the promoter is a baculovirus promoter.

36. A genetically engineered cell according to claim 32 wherein the cells are Sf9 cells.

25      37. A method for identifying a substance which modulates iPLA<sub>2Y</sub> expression, the method comprising: (1) contacting a candidate substance with a repressor binding site and detecting binding to said site, or (2) contacting a candidate substance with cells capable of expressing iPLA<sub>2Y</sub> or a fragment thereof and measuring the expression of iPLA<sub>2Y</sub> or fragment thereof by the cells, wherein a level of expression greater or less than that in absence of the substance indicates activity in modulating iPLA<sub>2Y</sub> expression.

CALCIUM INDEPENDENT PHOSPHOLIPASE A<sub>2</sub> $\gamma$   
AND METHODS THEREFOR

ABSTRACT OF THE DISCLOSURE

A novel human phospholipase, iPLA<sub>2</sub> $\gamma$  (iPL<sub>2</sub> $\gamma$ ), is described. The complete genomic organization, complete nucleic acid sequence, and amino acid sequence have been identified. The *sn*-2-lipase activity of iPL<sub>2</sub> $\gamma$  is also described. In addition, methods for detecting and monitoring patient levels of iPL<sub>2</sub> $\gamma$  are described, as well as methods for treating disease conditions by modulating the activity of iPL<sub>2</sub> $\gamma$ .

5

**FIGURE 1 (SHEET 1)**

1	TGGAAGCTCAGCTGATGCAGGCCGGTTGGAGCTCATGCCGGAACGGAGTC	60
61	GCCGCTGCGAGCCCTAGTGACTGGGCCATCCGATTGTCTCCTCCAAGGTCTAC	120
121	ATGATTACCTGAAGTTAATAAGTAAGACCATGAATTATGGCATTCTTAATGAAGCGT	180
181	TCAAGAAGTGAGAGAATGTCATAGAAATAATGATTAAAGTTAAGTTATGTCTATAATCTG	240
241	ACTGTAGATATATTTACCTCCTTAGTAATGCAAGAAGTGTGTTGGGAAGCAGAGA	300
	T V D I Y I Y L L S N A R S V C G K Q R	
301	AGCAAGCACTGTATTCTGTCTCACCTAACGTTACTGGAGGATAAGCCACATCAGT	360
	S K Q L Y F L F S P K H Y W R I S H I S	
361	CTACAAAGAGGTTTCATACAAACATAATAAGATGTAATTGGACCAAAGTGAAAGCACAT	420
	L Q R G F H T N I I R C K W T K S E A H	
421	TCTTGCGAGTAAGCAGCTGTACTCTCAAGCAACCATGGTTACATATTGGATTGAA	480
	S C S K H C Y S P S N H G L H I G I L K	
481	CTTAGCAGTTCTGCTCCCAGGGACTTACAAAGTGAACATTGTATGTCCTGTTAA	540
	I S T S A P K G L T K V N I C M S R I K	
541	AGTACTTGAACTCTGTTCAAAGGCTGTTGGCAATCAAATGAAATGATTTCACGT	600
	S T L N S V S K A V F G N Q N E M I S R	
601	TTAGCTCAATTAAGCCAAGTCCAAATTAAAGAAAGTATCGGATAGTGGCTGGTTA	660
	I A Q F K P S S Q I L R K V S D S G W L	
661	AAACAGAAAACATCAAACAAAGCCATCAAATCTCTGAAAAATATAGTGACAATCAGCA	720
	K Q K N I K Q A I K S L K K Y S D K S A	
721	GAAAAGAGTCCTTCCAGAAGAGAAAAGTCACATTATAGACAAGAAGAAGATATAGGT	780
	E K S P F P E E K S H I I D K E E D I G	
781	AACCGCAGTCTTTCTTACACAAAGTTGAGACTCATCTAC	840
	K R S L F H Y T S S I T T K F G D S F Y	
841	TTTTATCAAATCATATTATTCATATTCAAACGTAAGGAAAATGTCTCAACAAAG	900
	F L S N H I N S Y F K R K E K M S Q Q K	
901	GAAAATGACATTTCCGGACAAATCAGAACTTGAGATAAAAGTAGAGAGGGAAA	960
	E N E H F R D K S E L E D K K V E E G K	
961	TAAAGATCTCCAGATCCTGGCATCTGGCTTAAAGCCAGGCTCAGAATCTGTACATACG	1020
	I R S P D P G I L A Y K P G S E S V H T	
1021	GTGGACAAGCCTACCAAGTCCTCTGGATAACCTGATGTCTCAAGTTCAACTAACAA	1080

**FIGURE 1 (SHEET 2)**


V	D	K	P	T	S	P	S	A	I	P	D	V	L	Q	V	S	T	K	Q
1081	AGTATTGCTAACTTCTTCTCGTCCCACGGAAAGGTGACAAGCTTAGGGTTAT	1140																	
S	I	A	N	F	L	S	R	P	T	E	G	V	Q	A	L	V	G	G	Y
1141	ATGGTGGACTTGTCCCCAATTAAAGTATGATTCAGAGACTCAGTCAGAACAGGA	1200																	
I	G	G	L	V	P	K	L	K	Y	D	S	K	S	Q	S	E	E	Q	E
1201	GAGCCTGCTAAACTGATCAGGCTGTCAGCAAGACAGAACAGAATGCCAGAGGAAAGCGT	1260																	
E	P	A	K	T	D	Q	A	V	S	K	D	R	N	A	E	E	K	K	R
1261	TTATCTCTCAGCGAGAAAAGATTATCGCAAGGGTGAGTATGATAACAGGACCCGGCA	1320																	
L	S	L	Q	R	E	K	I	I	A	R	V	S	I	D	N	R	T	R	A
1321	TTAGTTCAAGGCATTAAGAACAACTGACCCAAGCTCTGCATTAAGGGTTGAGAA	1380																	
L	V	Q	A	L	R	R	T	T	D	P	K	L	C	I	T	R	V	E	E
1381	CTGACTTTCATCTCTAGGAATTCTCTGAAGGAAAGGACTGGCTGTCAGGAAAGGA	1440																	
L	T	F	H	L	L	E	F	P	E	G	K	G	V	A	V	K	E	R	I
1441	ATTCATATTAACTGAGACAAATTAGGATGAAACTCTCAGGCTGCAAGGAAAGGAA	1500																	
I	P	Y	L	L	R	L	R	Q	I	K	D	E	T	L	Q	A	A	V	R
1501	GAAATTGAGGCCCTAATGGCTATGGATCCAGTGAAAGGGAGAGGAATCCGAATTCTC	1560																	
E	I	L	A	L	I	G	Y	V	D	P	V	K	G	R	G	I	R	I	L
1561	TCAATTGATGGGGAGGAACAAGGGCGTGGTCTCCAGACCCCTACGAAATTAGTT	1620																	
S	I	D	G	G	G	T	R	G	V	V	A	L	Q	T	L	R	K	L	V
1621	GAACCTACTCAGAAGCCAGTTCATCAGCTCTTGATTACATTGGGTGTAAGCACAGGT	1680																	
E	L	T	Q	K	P	V	H	Q	L	F	D	Y	I	C	G	V	S	T	G
1681	GCCATATTAGCTTCACTGTTGGGTGTTCTATGCCCTGGATGAATGGAACTT	1740																	
A	I	L	A	F	M	L	G	L	F	H	M	P	L	D	E	C	E	E	L
1741	TATCGAAATTAGGATCAGATGTTTCACAAATGTCATGTTGGAACAGTAAATG	1800																	
Y	R	K	L	G	S	D	V	F	S	Q	N	V	I	V	G	T	V	K	M
1801	AGTTGGAGGCCATGCATTTATGACAGTCACACATGGAAACATTCTTAAGGATAGGATG	1860																	
S	W	S	H	A	F	Y	D	S	Q	T	W	E	N	I	L	K	D	R	M
1861	GGATCTGCACTGATGATGAAACAGCAAGAACCCCCACATGTCTTAAGGTAGCTGCTGTA	1920																	
G	S	A	L	M	I	E	T	A	R	N	P	T	C	P	K	V	A	A	V
1921	AGTACCATAGTAAATAGAGGGATAACACCCAAAGCTTGTGTTCAAGAACTATGGTCAT	1980																	
S	T	I	V	N	R	G	I	T	P	K	A	F	V	F	R	N	Y	G	H
1981	TTTCCTGGAATCAACTCTCATTATTGGGAGGCTGTCAGTATAAATGTGGCAGGCCATT	2040																	
F	P	G	I	N	S	H	Y	L	G	G	C	Q	Y	K	M	W	Q	A	I

**FIGURE 1 (SHEET 3)**

2041	AGAGCCTCATCTGCTCCAGGCTACTTTGCAGAATATGCATTGGAAATGATCTCAT	2100
R	A S S A A P G Y F A E Y A L G N D L H	
2101	CAAGATGGAGGTTCGCTTCTGAATAACCCCTCGGCATTAGCTATGCATGAGTGTAAATGT	2160
Q	D G G L L L N N P S A L A M H E C K C	
2161	CTTTGCCAGATGTGCCGTAGAGTGCATAGTATCCCTGGGCACTGGACGTTATGAGAGT	2220
I	W P D V P L E C I V S L G T G R Y E S	
2221	GATGTGAGAACACGGTAACACACAAGCTAACTTCTAATGTTAACAC	2280
D	V R N T V T Y T S L K T K L S N V I N	
2281	AGTGCTACAGATAACAGAAGAAGTCCATATAATGCTTGATGGCCTGTTACCTCCTGACACC	2340
S	A T D T E E V H I M L D G L L P P D T	
2341	TATTTAGATTCAATCCGTAAATGTGTAAACATACCTCTAGATGAAAGTCAAATGAA	2400
Y	F R F N P V M C E N I P L D E S R N E	
2401	AGGCTGGATCAGCTGCAGTTGGAAGGGTTGAAATACATAGAAAGAAATGAAACAAAAATG	2460
K	L D Q L Q L E G L K Y I E R N E Q K M	
2461	AAAAAAAGTTGCAAAATATTAAAGTCAGAAAAACAACTCTGCAGAAATTAATGATTGG	2520
K	K V A K I L S Q E K T T L Q K I N D W	
2521	ATAAAATTTAAACTGATATGTATGAAGGACTTCCATTCTTCAAAATTGTGATGAGTA	2580
I	K L K T D M Y E G L P F <u>S</u> <u>K</u> L -	
2581	TATGCTTATGTTCTCATAAATGAAGGTCTGTTAGAAGATCAACCCATTCAAATAAGGAA	2640
2641	TGTGGGGTTGCACCATGAGTTAACTTGTAAAGTGTAAATTAGCTTAGTAACTCCCTACTGTGCTA	2700
2701	AGACGGTCTCACCAAGCTGCATAGCACAGAGAATACGTATGAAATTCTGGAGAACCTCTGAAA	2760
2761	GGGAACACTAGGTTTAAGATGTTAAATTAGCTAAGCTTGTAACTCCCTACTGTGCTA	2820
2821	GTAGATTTAGATATTGGTTTATTTGTGATGTGTGAAATATAATATG	2880
2881	TGCCGAACAAAGAACCGAAAGCTATATTGTACTGTGTTACTTTACTTGTCTCATATA	2940
2941	CATGTGAAATTATGTGATCTTATTCATATGGAAAGCTAATTCTCTTAA	3000
3001	ATTACATTACCTAATATTCTCACTAGCTATGTCTTCAATCCACACTGCCTTTATGT	3060
3061	ATATCATCTAAATAGATGAGAAATGGAAATTCTCTTAAAGTATTITACATTG	3120
3121	ACAAAAAGAACCGAGATACAGTTCTTACATGTTAACATTGTTGG	3180
3180	TAAAAAGGTGAAGTTCAGTCACCAACTTTACCCCTGAATTCAGATAATGCTA	3240
3241	TATTAACCTTCCAGATCTAACACTAGCTTATCTCCCCTGTTAAATGTTGAACT	3300
3301	TACTGAGGAGATATTCTATCATTAACAAATAACTATTAAATCTGTGTTAA	3360
3361	AGGCTAATGTCATTAAATAATTGTTGTCATAATGCTCCCCTTAGCCTTGA	3420

**FIGURE 2**

## iPLA<sub>2</sub>γ Splice Variants



open boxes are noncoding regions  
shaded regions are putative coding regions  
stippled lines represent intron splicing

**FIGURE 3**

**Splice Variants of iPLA<sub>2</sub>γ**

4 / 5 / 00

| **Exon 1**

1 TGGAAAGCTCAGCTGATGCAGGCCGGTTGAGCTGGACGTCA  
2 TGGAAAGCTCAGCTGATGCAGGCCGGTTGAGCTGGAC  
3 TGGAAAGCTCAGCTGATM CAGGCCGGTTGGAGCTGGAC  
  Q A G W S S G R H C R E R A S R R C S P S D

81 | **Exon 2**

1 TCGGGCCTGCATCCGGATTGTCCTTCTCCCTCAAGGTCTACATGATTACCTGAAGTTAATAAGTAA  
2 TGCGGGCCTGCATCCGG.....  
3 TCGGGCCTGCATCCGGATTGTCCTCTCCCTCCAAGGTCTACATGATTACCTGAAGTTAATAA  
  C G L H P D C L L L Q G L H D Y L K F N N

161

1 GCATTTCTTAATGAAGCGTTCAAAGAAGTGAGAGAATGTCA  
2 GCATTINTTAATGAAGCGTTCAAAGAAGTGAGAGAATGTCA  
3

140

  M S I N L

160 | **Exon 3**

1 TGGAGCTTAAAGTGTCTTAAAGTGTCTTAAATCTG  
2 GCATTINTTAATGAAGCGTTCAAAGAAGTGAGAGAATGTCA  
3

220

1 T V D I Y I Y L L S N A R S V C G K Q R S K Q L Y F L  
2 ACTGTAGATATATATTACCTCCTTAGTAATGCAAGAAGTGTGGGGAA  
3 .....TAATGCAAGAAGTGTTGGGAAGCAGAGAACCAACTGTATTCTT  
  N A R S V C G K Q R S K Q L Y F L

FIGURE 4 (SHEET 1)

Full-length iPLA $2\gamma$

Primers for PCR amplification of full-length 88kDa iPLA $2\gamma$ :

Sense primer M444 5'-TTTGTCGACATGTCTATTAACTGTGACTGTAGATA-3'

Reverse primer M458 5'-GCATAGCATGCTCACAAATTGAAAGAATGGAGTCC-3'

Sequence of 88kDa iPLA $2$  gamma:

atgtcttattaaatctgtactgttagatatatatattttacctacttagtaatgcaagaagtgtt  
M S I N L T V D I Y I Y L L S N A R S V  
tgtggaaagcagaagaagcaactgttattttctgtttatcacctaagcattactggagg  
C G K Q R S K Q L Y F L F S P K H Y W R  
ataagccacatcgactacaagaggtttcatacaaacataaaatagatgttaatggacc  
I S H I S L Q R G F H T N I I R C K W T  
aaaagtgaagcacatcttcgcagaactgcactctccaaagcaaccatggtttacat  
K S E A H S C S K H C Y S P S N H G L H  
atgggattttgaaacttagcactctgtcccaaggacttacaaaatgtgaacatttgt  
I G I L K L S T S A P K G L T K V N I C  
atgtcccgatttaaaatgtactttgaactctgtttcaaaaggctgtttggcaatcaaat  
M S R I K S T L N S V S K A V F G N Q N  
gaaatgatttcacgtttagctcaatttaaagccaagttccaaattttaagaaaaatcg  
E M I S R L A Q F K P S S Q I L R K V S  
gatagtggctggtaaaacagaaaaatcaaaacaaaggcatcaaatctctgtaaaaatat  
D S G W L K Q K N I K Q A I K S L K K Y  
agtgacaatcagcagaaaaagagtccctttccagaagagaaaaatgcacattatagacaaa  
S D K S A E K S P F P E E K S H I I D K  
gaagaagatataggtaaacgcgcacttttccattacacaagttctataaccacaaaatt  
E E D I G K R S L F H Y T S S I T T K F  
ggagactcattttatcaaatcatattttcaatcattttcaacgtaaaggaaaaa  
G D S F Y F L S N H I N S Y F K R K E K  
atgtctcaacaaaaggaaaatgaacatattttcaaggacaatcagaacttgaagataaaaag  
M S Q Q K E N E H F R D K S E L E D K K

**FIGURE 4 (SHEET 2)**

gtagaagagggaaathtaagatccagatcctggcatctggcttataaggccaggctca  
V E E G K L R S P D P G I L A Y K P G S  
gaatctgtacatacgggacaaggcataacttcctctgcgataacctgtatgttcaa  
E S V H T V D K P T S P S A I P D V L Q  
gtttcaactaacaacttgcataactttctcgatcccacggaaagggttacaagct  
V S T K Q S I A N F L S R P T E G V Q A  
tttagtaggttatattggacttgcccaattaatgattcaaaagagtca  
L V G G Y I G G L V P K L K Y D S K S Q  
tcagaagaacaggaagagcctgtctaaaactgtatcaggctgtcagcaagagaatgca  
S E Q E P A K T D Q A V S K D R N A  
gaggagaaaaagcgtttatctcttcagcgaaaaagattatcgcagggtgaggattgt  
E E K R L S I Q R E K I I A R V S I D  
aacaggaccggcatttagttcaggcattaagaagaacaactgacccaaagctctgcatt  
N R T R A L V Q A L R R T T D P K I C I  
acttaggttgaagaactgactttcatcttcagaatttcctgaagggaaaggagtggct  
T R V E L T F H L L E F P E G K G V A  
gtcaagggaaaattttccatatttacgacttgagacaatataaggatgaaacttt  
V K E R I I P Y L L R L R Q I K D E T L  
caggctgcagtttagaaaaatttggccctaatttgctatgtggatccaggatgaaaggaga  
Q A A V R E I L A L I G Y V D P V K G R  
ggaatccgaattctcaatttgatggggaggaacaaggcggtggctccagacc  
G I R I L S I D G G T R G V V A I L Q T  
ctacggaaaatttagttgaacttactcagaaggcaggatcatcagctcttgattacattgt  
L R K L V E L T Q K P V H Q L F D Y I C  
gggtgttgcacaggccatattagttcatgtgggtgtttcatatgccttggat  
G V S T G A I L A F M L G L F H M P L D  
gaatgtgaggaacttatacgaaaataggatcagatgtatttcacaaaatgttcatgtt  
E C E L Y R K L G S D V F S Q N V I V  
ggAACAGTAAATGAGTTGGAGCCATGCATTTATGACAGTCACACATGGAAAACATT  
G T V K M S W S H A F Y D S Q T W E N I  
cttaaggataggatggatctgcactgtatggaaacagcaagaaacccacatgtcct  
L K D R M G S A L M I E T A R N P T C P  
aaggttagctgttacaatagatggataacacccaaagcttttgttca

FIGURE 4 (SHEET 3)

K V A A V S T I V N R G I T P K A F V F  
agaaactatggtcattttcctggaatcaactcttatttggagggtcgtaataaa  
R N Y G H F P G I N S H Y L G G C Q Y K  
atgtggcaggccatttagagcctcatctgctgctccaggctactttgcagaatatgcattg  
M W Q A I R A S S A A P G Y F A E Y A L  
gaaaatgtttcatcaagatggaggttgatctgaataacccttcggcatttagctatg  
G N D L H Q D G G L L L N N P S A L A M  
catgagtgtaaatgtctttggccagatgtggcgtagatgtgcataatccctgggcact  
H E C K C L W P D V P L E C I V S L G T  
ggacgttatgagatgtgagaacacggtaacatacacaaagcttgaaaactaaact  
G R Y E S D V R N T V T Y T S I K T K L  
tctaattgttatcaacagtgtctacagatacagaagaagtcctataatgtgttgatggcctg  
S N V I N S A T D T E E V H I M L D G L  
ttacccctgacacatttttagattcaatcctgtaatgtgtgaaaacatacccttagat  
L P P D T Y F R F N P V M C E N I P L D  
gaaagtgcgaaatgaaaagctggatcagctgcagtggaaagggtgaaatacatagaaga  
E S R N E K L D Q I Q L E G L K Y I E R  
aatgaacaaaaaatgaaaaagttgcaaaaatattaagtcaagaaaaacaactctgcag  
N E Q K M K K V A K I L S Q E K T T L Q  
aaaatataatgtggataaaataaaaactgtatgtatgtggacttccattttca  
K I N D W I K L K T D M Y E G L P F F S  
aaattgtga  
K L -

**FIGURE 5 (SHEET 1)**

**Sequence of 77kDa iPLA<sub>2</sub> gamma:  
starting at amino acid 101 (nucleotide 301)**

**Primers for PCR amplification of 77kDa iPLA<sub>2</sub>γ:**

Sense primer m534                    5'-TGAACGTCGACATGTCCCGTATTAAA-3'  
Reverse primer M458                    5'-GCATAGCATGCTCACAAATTGAAAGAATGGAAAGTCC-3'

atgtcccgattaaagaactttgaactctgtttcaaaggctgttttggcaatcaaatt  
M S R I K S T L N S V S K A V F G N Q N  
gaaatgattcacgttagctcaatttaagccaagttccaaatttaagaaaagtatcg  
E M I S R L A Q F K P S S Q I L R K V S  
gatagtggctggtaaacagaaaaacatcaaacaagccatcaaactctgtaaaaatat  
D S G W L K Q K N I K Q A I K S L K K Y  
agtgacaatcagcagaaaagagtcccttccagaaagaaaaagtcacattagacaaa  
S D K S A E K S P F P E K S H I I D K  
gaagaagatataggtaaacgcagtcctttcattacacaagttctataaccacaaaattt  
E E D I G K R S L F H Y T S S I T T K F  
ggagactcattctacttttatcaaatcatatattcatattcaaacgtaaggaaaaa  
G D S F Y F L S N H I N S Y F K R K E K  
atgtctcaacaaaagaaaatgaacatccggacaatcagaacttgaagataaaaag  
M S Q K E N E H F R D K S E L E D K K  
gtagaagagggaaatthaagatctccagatcctggatctggattataaggcaggtca  
V E E G K L R S P D P G I L A Y K P G S  
gaatctgtacatacggtgaccataaactgtccctctgtcgataactgtatgttcttcaa  
E S V H T V D K P T S P S A I P D V L Q  
gtttcaactaaacaagaatgttgcataactttcttcgtcccacggaaagggttacaagct  
V S T K Q S I A N F L S R P T E G V Q A  
tttagtaggtgttatattgtggacttgtgtcccaatcaaagatgtatgttcaagagtcag  
L V G G Y I G G L V P K L K Y D S K S Q  
tcagaagaacaggaagcgtgctaaactgtatgtcaggctgtcagcaagacagaatgca  
S E E Q E P A K T D Q A V S K D R N A

FIGURE 5 (SHEET 2)

gaggagaaaagcgtttatctcttcagcgagaaagattatcgcagaagggtgagtttatgtat  
E E K K R L S L Q R E K I I A R V S I D  
aacaggaccggcatttagttcaggcattaagaacaactgacccaaagctctgcatt  
N R T R A L V Q A L R R T T D P K L C I  
acttaggttgaagaactgactttcatctcttagaattcctgaaggaaaggagtggct  
T R V E E L T F H L L E F P E G K G V A  
gtccaaggaaagaattttccatattttacgactgagacaatataaggatgaaactctt  
V K E R I I P Y L L R Q I K D E T L  
caggctgcagtttagaaattttggccctaatttgctatgtggatccaggatgaaaggaga  
Q A A V R E I L A L I G Y V D P V K G R  
ggaatccgaattctcaatttgatgggaggaacaaggcggtggctccagacc  
G I R I L S I D G G T R G V V A L Q T  
ctacgaaaatttagttgaacttaactcagaagccagttcatcagctcttgattacattgt  
L R K L V E L T Q K P V H Q L F D Y I C  
ggtagcacaggtgccatatttagttcatgtgggtgtttcatatgccttggat  
G V S T G A I L A F M L G L F H M P L D  
gaatgtgaggaactttatcgaaaatttagatcagatgtatccaaaatgtcatttgtt  
E C E L Y R K L G S D V F S Q N V I V  
ggaacagtaaaatgagttggagccatgcattttatgacagtcaaacatggaaaacatt  
G T V K M S W S H A F Y D S Q T W E N I  
cttaaggataggatggatctgcactgtatgttggaaacagcaagaacccacatgtcct  
L K D R M G S A L M I E T A R N P T C P  
aaggttagctgtgttaagtaccatagtaaatagaggataacacccaaagctttgtgttc  
K V A A V S T I V N R G I T P K A F V F  
agaaaactatggtcattttcatttggaaatcaactctcattatttggagggtgtcagtataaa  
R N Y G H F P G I N S H Y L G G C Q Y K  
atgtggcaggccatttaggcctcatctgtgtccaggtaactttgcagaatatgtcattg  
M W Q A I R A S S A A P G Y F A E Y A L  
ggaaatgttccatcaagatggaggttgcttgcataaacccttcggcatttagctatg  
G N D L H Q D G G L L N N P S A L A M  
catgagttgttaatgtctttggccagatgtggcgttagatgtgcataatccctggcact  
H E C K C L W P D V P L E C I V S L G T  
ggacgttatgagatgtgagaaacacacggtaacatacacaagcttgaaactaaactt

FIGURE 5 (SHEET 3)

G R Y E S D V R N T V T Y T S I K T K L  
tctaatgttatcaacagtgtcacagatacagaagaatgtccataatgttgatggcctg  
S N V I N S A T D T E E V H I M L D G L  
ttacacctgacacacctttagattcaatcctgtaatgtgtgaaaacatacccttagat  
L P P D T Y F R F N P V M C E N I P L D  
gaaagtgcgaaatgaaagctggatcagtcgtgcagttggaaagggttggaaatacatagaaga  
E S R N E K L D Q L Q L E G L K Y I E R  
aatgaacaacaaatgaaaaatgtgcacaaaatattaagtcaagaaaaacaactctgcag  
N E Q K M K K V A K I L S Q E K T T L Q  
aaaaatataatgtgataaaataaaactgtatgtatgaaaggactccattttca  
K I N D W I K L T D M Y E G I P F F S  
aaatttgtga  
K L -

FIGURE 6 (SHEET 1)

Sequence of 74kDa iPLA<sub>2</sub> gamma:  
starting at amino acid 122 (nucleotide 364)

Primers for PCR amplification of 74kDa iPLA<sub>2</sub>γ:

Sense primer m533                    5'-TCAAGTCGACATGATTCACCGTTAGC-3'  
Reverse primer M458                    5'-GCATAGCATGCTCACAAATTGAAAAGAATGGAAAGTCC-3'

atgatttcacgtttagctcaatttaagccaaagtcccaatttaagaaaaagtatcg  
M I S R L A Q F K P S S Q I L R K V S  
gatagtggctggttaaaaacagaaaaacatcaaacaaggcatcaaatctctgaaaaatat  
D S G W L K Q K N I K Q A I K S L K K Y  
agtgacaatcagcagaaaaagactgccttccagaagagaaaaagtcacattatagacaaa  
S D K S A E K S P F P E E K S H I I D K  
gaagaagatataaggttaaacgcagtcttttcattacaacaagttctataaccacaaaatt  
E E D I G K R S I F H Y T S S I T T K F  
ggagactcaattctacttttatcaaataattcatattcaaacgtaaaggaaaa  
G D S F Y F L S N H I N S Y F K R K E K  
atgtctcaacaaaagaaaatgaacacattccggacaatcagaacttgaagataaaag  
M S Q K E N E H F R D K S E L E D K K  
gtagaagagggaaatthaagatctccagatcctggcatcctggcttataagccaggctca  
V E E G K L R S P D P G I L A Y K P G S  
gaatctgtacatacggacaaaggctacaagtccttctggatactgtatgttcttcaa  
E S V H T V D K P T S P S A I P D V L Q  
gttcaactaaacaagaatgtacttctttctgtccacggaaagggtgtacaagct  
V S T K Q S I A N F L S R P T E G V Q A  
tttagtaggtgttatattggggacttgcccataatcaaagtatgattcaagagtcag  
L V G G Y I G G L V P K L K Y D S K S Q  
tcagaacaacaggaagagcgtctgctaaaactgtatcaggctgtcagcaagacagaaatgc  
S E E Q E E P A K T D Q A V S K D R N A  
gaggagaaaaagcgttatctcttcagcgagaaaaagattatcgcaagggtaggtattgt  
E E K K R L S L Q R E K I I A R V S I D

FIGURE 6 (SHEET 2)

aacaggaccggcattagttcaggcattaagaacaactgacccaaactgcatt  
N R T R A L V Q A L R R T T D P K L C I  
acttaggttgaagaactgactttcatcttcttagaatttcctgaaggaaaggagtggt  
T R V E E L T F H L L E F P E G K G V A  
gtcaaggaaagaattattccatattacgactgagacaaattaaggatgaaactctt  
V K E R I I P Y L L R L R Q I K D E T L  
caggctgcagttagagaaattttggccataattggctatgtggatccaggatgaaaggaga  
Q A A V R E I L A L I G Y V D P V K G R  
ggaatccgaattctcaatttgcattatgtggaggaaacaaggcggtgggtgtctccagacc  
G I R I L S I D G G G T R G V V A L Q T  
ctacgaaaatttagttgaacttactcagaagccagttcacgcattttgattacatttgt  
L R K L V E L T Q K P V H Q L F D Y I C  
ggtgttaaggcacaggccatattagcttcatgtgtgggtgtttcatatgcccttggat  
G V S T G A I L A F M L G L F H M P L D  
gaatgtgaggaacttatcgaaaatttaggtcagatgttgcattttcacaaaatgtcattgtt  
E C E E L Y R K L G S D V F S Q N V I V  
ggAACAGTAAATGAGTTGGAGCCATGCATTATGACAGTCAAACATGGAAAACATT  
G T V K M S W S H A F Y D S Q T W E N I  
cttaaggataaggatggatctgcactgtatgttgcattttcacaaaatgtcattgtt  
I K D R M G S A L M I E T A R N P T C P  
aaggtagctgttaagtaccatagtaaatagaggataaacacccaagctttgtgttc  
K V A A V S T I V N R G I T P K A F V F  
agaAAACTATGGTCATTTCCTGGAATCAACTCTCATTATTGGAGGCTGTCACTATAAA  
R N Y G H F P G I N S H Y L G G C Q Y K  
atgtggcaggcatttaggcctcatctgtgtccaggctactttgcagaatatgcattg  
M W Q A I R A S S A A P G Y F A E Y A L  
ggaaatgatttcattcaagatggagggttgcattgtgtttgtgtttgtgtttgtgtt  
G N D L H Q D G G I L L N N P S A L A M  
catgagtgtaaatgtttggccagatgtgtccaggctactttgcagaatatgcattg  
H E C K C L W P D V P L E C I V S L G T  
ggacgttatgagatgtgtgagaacacggtaacacaaactacaaactgaaactaaact  
G R Y E S D V R N T V T Y T S L K T K L  
tctaattatcaacaaatgtgttgcatacagatacagaagaactccatataatgtgttgcattgt

FIGURE 6 (SHEET 3)

S N V I N S A T D T E E V H I M L D G L  
ttacccctgacacacctttagattcaatcctgtgaaacatacccttagat  
L P P D T Y F R F N P V M C E N I P L D  
gaaagtcgaaaagctggatcagctgcagtggaaagggttgaaatacataagaaga  
E S R N E K L D Q L Q L E G L K Y I E R  
aatgaacaaaaatgaaaaatgtgcaaaaataatataactcaagaaaaacaactctgcag  
N E Q K M K K V A K I L S Q E K T T L Q  
aaaattaatgattgataaaataaaaactgatatagttatgaaaggactccattttca  
K I N D W I K L K T D M Y E G L P F F S  
aaattgtga  
K L -

**FIGURE 7 (SHEET 1)**


**Sequence of 63kDa iPLA<sub>2</sub> gamma**  
starting at amino acid 221 (nucleotide 661)


Sense primer M530                    5':GTAAGTCGACAATGTCCTCAACAAAAGG-3'  
Reverse primer M458                    5'GCATAGCATGCTCACAAATTGAAAGTCC-3')

atgtctcaacaaaaggaaatgaacattccgggacaatcagaacttgcgaaataaaaag  
M S Q Q K E N E H F R D K S E L E D K K  
gttagaagagggaaattaagaatctccagatcctggcatcctggcttataaagccaggctca  
V E E G K L R S P D P G I L A Y K P G S  
gaatctgtacatacggtggacaaggctacaactgccttctgcgataacctgatgttctcaa  
E S V H T V D K P T S P S A I P D V L Q  
gttcaactaaacaagaatttcttcgtccacggaaagggtacaagct  
V S T K Q S I A N F L S R P T E G V Q A  
ttagtaggtgttatattgttgactttgtccccaaatcaaaggatgtatcaagaggtcag  
L V G G Y I G G L V P K L K Y D S K S Q  
tcagaagaacaggaaagagcctgtctaaactgtatcaggctgtcagcaaaagacagaatgca  
S E E Q E P A K T D Q A V S K D R N A  
gaggagaaaagcgtttatctcttcagggagaaaggattatcgcaagggtgaggttatgt  
E E K K R L S L Q R E K I I A R V S I D  
aacaggaccggcatttagttcaggcattaagaacaactgtgacccaaagctctgcatt  
N R T R A L V Q A L R R T T D P K L C I  
actagggttgaactgtactttcatctttagaaatttgcgaaaggaaaggaggtggct  
T R V E E L T F H L L E F P E G K G V A  
gtcaaggaaagaattattccatatttacgactgtgagacaatataaggatgaaactctt  
V K E R I I P Y L L R L R Q I K D E T L  
caggctgcagtttagagaattttggccctaattggctatgtggatccagtcgtgaaaggaga  
Q A A V R E I L A L I G Y V D P V K G R  
ggaatccgaattctcaatttgcgtggaggaaacaaggggcggtgtctccagacc  
G I R I L S T D G G G T R G V V A L Q T  
ctacgaaaattagttgaaacttactcagaagccagttcatcagcttttgattacatttgt  
L R K L V E L T Q K P V H Q L F D Y I C

FIGURE 7 (SHEET 2)

Fig. 8





**FIG. 9**




FIG. 10




FIG. 11




FIG. 12






FIG. 13



**FIG. 14**






FIG. 16




FIG. 17





FIG. 18

# Translational Repression of iPLA<sub>2</sub> $\gamma$



25

Gamma Translation Repression Constructs  
4/25/00






FIG. 20

Additionally, iPLA $\gamma$  sequences were inserted by ligation of 15-23mer annealed phosphorylated oligonucleotide pairs 5' of full-length luciferase coding sequence cloned into pFASTBAC via Nofl/XbaI restriction sites and then luciferase activity of recombinant protein produced in the SF9 system was subsequently measured using the Luciferase Assay System of Promega.



**FIG. 22**



**Phosphorylated oligo pairs for sequence between nucleotide 364- 455  
for translational repression  
of iPLA2 gamma in the luciferase expression system:**

iPLA2γ atgatttcacgcgttagctcaatttaagccaaatttaaaggatcgatagtggatgtgtttaaacagaaaaatcaaaca  
1/2 tcgactgtttcacgcgttagctcaatt  
ggactaaatcgcaatcgagttAACGG

3/4 tcgactaaggccaaatccaaatttaa  
gattcggttcaagggttAAATCCGG

5/6 tcgacgaaaatcgatagtggctgg  
gcttttcatagcctatcaccggccccgg

7/8 tcgacttaaaacagaaaaacatcaaaca  
gaattttgtcttttgttagttgtccgg

**FIG. 23**




FIG. 24

## DECLARATION AND POWER OF ATTORNEY

Attorney's Docket No.

15060-00004

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:**CLACIUM INDEPENDENT PHOSPHOLIPASE A<sub>2</sub>, POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS THEREFOR**, the specification of which:

(check one)       is attached hereto  
                      was filed on \_\_\_\_\_ as Application Serial No. \_\_\_\_\_  
                      and was amended on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations §1.56(a).

I hereby claim priority benefits under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112. I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status (patented, pending, abandoned)</u>
_____	_____	_____
_____	_____	_____
_____	_____	_____

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below:

<u>Application Serial No.</u>	<u>Filing Date</u>	Additional provisional application numbers are listed on a supplemental page attached hereto.
_____	_____	_____
_____	_____	_____

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.  
*(list name and registration number)*

John S. Beulick, Reg. No. 33,338; Patrick W. Rasche, Reg. No. 37,916; Michael Tersillo, Reg. No. 42,180; Tara A. Nealey, Reg. No. 42,927; Bruce T. Atkins, Reg. No. 43,476, Alan L. Cassel, Reg. No. 35,842; Elizabeth D. Odell, Reg. No. 39,532; Donald R. Holland, Reg. No. 35,197; Stephen R. Cooper, Reg. No. 42,437; Robert E. Slenker, Reg. No. 45,112; Robert B. Reeser, III, Reg. No. 45,548, and Natu J. Patel, Reg. No. 39,559, all of Armstrong Teasdale, One Metropolitan Square, Suite 2600, St. Louis, MO 63102-2740

Send Correspondence to:

Donald R. Holland  
Armstrong Teasdale LLP  
One Metropolitan Square, Suite 2600  
St. Louis, MO 63102-2740

Direct Telephone Calls To:

Donald R. Holland  
314/621-5070

## DECLARATION AND POWER OF ATTORNEY

Attorney's Docket No.  
15060-00004

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application and any patent issued thereon.

## SOLE OR FIRST INVENTOR:

Full Name: Richard W. Gross

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: \_\_\_\_\_

Citizenship: \_\_\_\_\_

Post Office Address: \_\_\_\_\_

## SECOND JOINT INVENTOR, IF ANY:

Full Name: David J. Mancuso

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: \_\_\_\_\_

Citizenship: \_\_\_\_\_

Post Office Address: \_\_\_\_\_

## THIRD JOINT INVENTOR, IF ANY:

Full Name: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: \_\_\_\_\_

Citizenship: \_\_\_\_\_

Post Office Address: \_\_\_\_\_

## FOURTH JOINT INVENTOR, IF ANY:

Full Name: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: \_\_\_\_\_

Citizenship: \_\_\_\_\_

Post Office Address: \_\_\_\_\_

## FIFTH JOINT INVENTOR, IF ANY:

Full Name: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Residence: \_\_\_\_\_

Citizenship: \_\_\_\_\_

Post Office Address: \_\_\_\_\_